BeiGene (ONC) 10-Q 7 Aug 24 2024 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2024	Aug. 02, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-37686
Entity Registrant Name	BEIGENE, LTD.
Entity Incorporation, State or Country Code	E9
Entity Tax Identification Number	98-1209416
Entity Address, Street Address	c/o Mourant Governance Services (Cayman) Limited
Entity Address, Street Address Two	94 Solaris Avenue, Camana Bay
Entity Address, City	Grand Cayman
Entity Address, Country	KY
Entity Address, Postal Zip Code	KY1-1108
City Area Code	345
Local Phone Number	949-4123
Title of each class	American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol(s)	BGNE
Name of each exchange on which registered	NASDAQ
Entity Common Stock, Shares Outstanding		1,379,529,263
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Central Index Key	0001651308
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS ¥ in Thousands, $ in Thousands	Jun. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)
Current assets:
Cash and cash equivalents	$ 2,592,655	$ 3,171,800
Accounts receivable, net	529,449	358,027
Inventories, net	443,260	416,122
Prepaid expenses and other current assets	273,658	257,465
Total current assets	3,839,022	4,203,414
Property, plant and equipment, net	1,516,491	1,324,154
Operating lease right-of-use assets	103,633	95,207
Intangible assets, net	53,715	57,138
Other non-current assets	199,318	125,362
Total non-current assets	1,873,157	1,601,861
Total assets	5,712,179	5,805,275
Current liabilities:
Accounts payable	333,022	315,111
Accrued expenses and other payables	646,538	693,731
Tax payable	5,278	22,951
Operating lease liabilities, current portion	17,658	21,950
Research and development cost share liability, current portion	84,615	68,004
Short-term debt	851,657	688,366
Total current liabilities	1,938,768	1,810,113
Non-current liabilities:
Long-term bank loans	185,271	197,618
Operating lease liabilities, non-current portion	35,398	22,251
Deferred tax liabilities	15,942	16,494
Research and development cost share liability, non-current portion	119,012	170,662
Other long-term liabilities	51,533	50,810
Total non-current liabilities	407,156	457,835
Total liabilities	2,345,924	2,267,948
Commitments and contingencies
Shareholders’ equity:
Ordinary shares, $0.0001 par value per share; 9,500,000,000 shares authorized; 1,379,101,901 and 1,359,513,224 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	137	135
Additional paid-in capital	11,840,197	11,598,688
Accumulated other comprehensive loss	(140,474)	(99,446)
Accumulated deficit	(8,333,605)	(7,962,050)
Total shareholders’ equity	3,366,255	3,537,327
Total liabilities and shareholders’ equity	$ 5,712,179	$ 5,805,275

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Ordinary shares
Ordinary shares, par value (in dollars per share)	$ 0.0001	$ 0.0001
Ordinary shares, shares authorized (in shares)	9,500,000,000	9,500,000,000
Ordinary shares, shares issued (in shares)	1,379,101,901	1,359,513,224
Ordinary shares, shares outstanding (in shares)	1,379,101,901	1,359,513,224

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Total revenues	$ 929,166	$ 595,261	$ 1,680,818	$ 1,043,062
Gross profit	791,034	499,271	1,417,751	865,283
Operating expenses
Research and development	454,466	422,764	915,104	831,348
Selling, general and administrative	443,729	395,034	871,156	723,533
Amortization of intangible assets	0	188	0	375
Total operating expenses	898,195	817,986	1,786,260	1,555,256
Loss from operations	(107,161)	(318,715)	(368,509)	(689,973)
Interest income, net	13,225	15,070	29,385	31,086
Other expense, net	(11,984)	(63,818)	(10,222)	(45,515)
Loss before income taxes	(105,920)	(367,463)	(349,346)	(704,402)
Income tax expense	14,485	13,674	22,209	25,166
Net loss	$ (120,405)	$ (381,137)	$ (371,555)	$ (729,568)
Net loss per share, basic (in dollars per share)	$ (0.09)	$ (0.28)	$ (0.27)	$ (0.54)
Net loss per share, diluted (in dollars per share)	$ (0.09)	$ (0.28)	$ (0.27)	$ (0.54)
Weighted-average shares outstanding—basic (in shares)	1,361,082,567	1,360,224,377	1,358,315,145	1,357,211,308
Weighted-average shares outstanding— diluted (in shares)	1,361,082,567	1,360,224,377	1,358,315,145	1,357,211,308
Net loss per American Depositary Share (“ADS”), basic (in dollars per share)	$ (1.15)	$ (3.64)	$ (3.56)	$ (6.99)
Net loss per American Depositary Share (“ADS”), diluted (in dollars per share)	$ (1.15)	$ (3.64)	$ (3.56)	$ (6.99)
Weighted-average ADSs outstanding - basic (in shares)	104,698,659	104,632,644	104,485,780	104,400,870
Weighted-average ADSs outstanding - diluted (in shares)	104,698,659	104,632,644	104,485,780	104,400,870
Product revenue, net
Revenues
Total revenues	$ 921,146	$ 553,745	$ 1,668,064	$ 964,036
Cost of sales - product	138,132	95,990	263,067	177,779
Collaboration revenue
Revenues
Total revenues	$ 8,020	$ 41,516	$ 12,754	$ 79,026

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Net loss	$ (120,405)	$ (381,137)	$ (371,555)	$ (729,568)
Other comprehensive income (loss), net of tax of nil:
Foreign currency translation adjustments	(9,236)	(86,519)	(41,399)	(73,172)
Pension liability adjustments	406	0	406	0
Unrealized holding (loss) income, net	0	1,846	(35)	6,902
Comprehensive loss attributable to BeiGene, Ltd.	$ (129,235)	$ (465,810)	$ (412,583)	$ (795,838)

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating activities:
Net loss	$ (371,555)	$ (729,568)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	50,224	42,346
Share-based compensation expenses	219,304	178,693
Gain on deconsolidation of a subsidiary	(3,735)	0
Amortization of research and development cost share liability	(35,039)	(22,669)
Other items, net	5,413	2,930
Changes in operating assets and liabilities:
Accounts receivable	(173,896)	(131,923)
Inventories	(35,949)	(53,598)
Other assets	(32,233)	(30,627)
Accounts payable	2,192	(32,678)
Accrued expenses and other payables	(28,256)	(8,082)
Deferred revenue	216	(72,577)
Other liabilities	(846)	88
Net cash used in operating activities	(404,160)	(857,665)
Investing activities:
Purchases of property, plant and equipment	(266,528)	(247,055)
Purchase of intangible asset	(4,674)	0
Proceeds from sale or maturity of investments	2,655	567,500
Purchase of in-process research and development	(31,800)	0
Other investing activities	(20,516)	(11,582)
Net cash (used in) provided by investing activities	(320,863)	308,863
Financing activities:
Proceeds from long-term loan	9,053	15,771
Repayment of long-term loan	(14,020)	0
Proceeds from short-term loans	324,412	161,846
Repayment of short-term loans	(157,490)	(66,574)
Proceeds from option exercises and employee share purchase plan	20,355	35,169
Other financing activities	3,000	0
Net cash provided by financing activities	185,310	146,212
Effect of foreign exchange rate changes, net	(28,340)	(50,873)
Net decrease in cash, cash equivalents, and restricted cash	(568,053)	(453,463)
Cash, cash equivalents, and restricted cash at beginning of period	3,185,984	3,875,037
Cash, cash equivalents, and restricted cash at end of period	2,617,931	3,421,574
Supplemental cash flow information:
Cash and cash equivalents	2,592,655	3,410,368
Short-term restricted cash	23,155	9,693
Long-term restricted cash	2,121	1,513
Income taxes paid	45,636	32,529
Interest expense paid	24,148	10,015
Supplemental non-cash information:
Capital expenditures included in accounts payable and accrued expenses	115,564	95,404
Increase in equity investment from deconsolidation of a subsidiary	$ 40,798	$ 0

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY - USD ($) $ in Thousands	Total	Ordinary Shares	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit
Balance at the beginning of period (in shares) at Dec. 31, 2022		1,356,140,180
Balance at the beginning of period at Dec. 31, 2022	$ 4,383,355	$ 135	$ 11,540,979	$ (77,417)	$ (7,080,342)
Increase (Decrease) in Stockholders' Equity
Use of shares reserved for share option exercises (in shares)		(98,774)
Exercise of options, ESPP and release of RSUs (in shares)		6,610,695
Exercise of options, ESPP and release of RSUs	28,657	$ 1	28,656
Share-based compensation	75,322		75,322
Other comprehensive (loss) income	18,403			18,403
Net loss	(348,431)				(348,431)
Balance at the end of period (in shares) at Mar. 31, 2023		1,362,652,101
Balance at the end of period at Mar. 31, 2023	4,157,306	$ 136	11,644,957	(59,014)	(7,428,773)
Balance at the beginning of period (in shares) at Dec. 31, 2022		1,356,140,180
Balance at the beginning of period at Dec. 31, 2022	4,383,355	$ 135	11,540,979	(77,417)	(7,080,342)
Increase (Decrease) in Stockholders' Equity
Net loss	(729,568)
Balance at the end of period (in shares) at Jun. 30, 2023		1,376,251,336
Balance at the end of period at Jun. 30, 2023	3,798,559	$ 137	11,752,019	(143,687)	(7,809,910)
Balance at the beginning of period (in shares) at Mar. 31, 2023		1,362,652,101
Balance at the beginning of period at Mar. 31, 2023	4,157,306	$ 136	11,644,957	(59,014)	(7,428,773)
Increase (Decrease) in Stockholders' Equity
Use of shares reserved for share option exercises (in shares)		220,116
Exercise of options, ESPP and release of RSUs (in shares)		13,379,119
Exercise of options, ESPP and release of RSUs	3,692	$ 1	3,691
Share-based compensation	103,371		103,371
Other comprehensive (loss) income	(84,673)			(84,673)
Net loss	(381,137)				(381,137)
Balance at the end of period (in shares) at Jun. 30, 2023		1,376,251,336
Balance at the end of period at Jun. 30, 2023	$ 3,798,559	$ 137	11,752,019	(143,687)	(7,809,910)
Balance at the beginning of period (in shares) at Dec. 31, 2023	1,359,513,224	1,359,513,224
Balance at the beginning of period at Dec. 31, 2023	$ 3,537,327	$ 135	11,598,688	(99,446)	(7,962,050)
Increase (Decrease) in Stockholders' Equity
Use of shares reserved for share option exercises (in shares)		(3,634,952)
Exercise of options, ESPP and release of RSUs (in shares)		3,646,097
Exercise of options, ESPP and release of RSUs	15,663	$ 1	15,662
Share-based compensation	88,667		88,667
Deconsolidation of a subsidiary	2,052		2,052
Other comprehensive (loss) income	(32,198)			(32,198)
Net loss	(251,150)				(251,150)
Balance at the end of period (in shares) at Mar. 31, 2024		1,359,524,369
Balance at the end of period at Mar. 31, 2024	$ 3,360,361	$ 136	11,705,069	(131,644)	(8,213,200)
Balance at the beginning of period (in shares) at Dec. 31, 2023	1,359,513,224	1,359,513,224
Balance at the beginning of period at Dec. 31, 2023	$ 3,537,327	$ 135	11,598,688	(99,446)	(7,962,050)
Increase (Decrease) in Stockholders' Equity
Other comprehensive (loss) income	(41,028)
Net loss	$ (371,555)
Balance at the end of period (in shares) at Jun. 30, 2024	1,379,101,901	1,379,101,901
Balance at the end of period at Jun. 30, 2024	$ 3,366,255	$ 137	11,840,197	(140,474)	(8,333,605)
Balance at the beginning of period (in shares) at Mar. 31, 2024		1,359,524,369
Balance at the beginning of period at Mar. 31, 2024	3,360,361	$ 136	11,705,069	(131,644)	(8,213,200)
Increase (Decrease) in Stockholders' Equity
Use of shares reserved for share option exercises (in shares)		2,418,936
Exercise of options, ESPP and release of RSUs (in shares)		17,158,596
Exercise of options, ESPP and release of RSUs	4,492	$ 1	4,491
Share-based compensation	130,637		130,637
Other comprehensive (loss) income	(8,830)			(8,830)
Net loss	$ (120,405)				(120,405)
Balance at the end of period (in shares) at Jun. 30, 2024	1,379,101,901	1,379,101,901
Balance at the end of period at Jun. 30, 2024	$ 3,366,255	$ 137	$ 11,840,197	$ (140,474)	$ (8,333,605)

Description of Business, Basis

Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies	Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies Description of business BeiGene, Ltd. (the “Company”, “BeiGene”, “it”, “its”) is a global oncology company discovering and developing innovative treatments that are more accessible and affordable to cancer patients worldwide. The Company currently has three approved medicines that were internally discovered and developed, including BRUKINSA ® (zanubrutinib), a small molecule inhibitor of Bruton’s Tyrosine Kinase (“BTK”) for the treatment of various blood cancers; TEVIMBRA ® (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX ® (pamiparib), a selective small molecule inhibitor of PARP1 and PARP2. The Company markets BRUKINSA in the United States (“U.S.”), the People’s Republic of China (“China” or the “PRC”), the European Union (“EU”), the United Kingdom (“UK”), Canada, Australia, and additional international markets; TEVIMBRA (tislelizumab) in the U.S., EU and China; and PARTRUVIX in China. By leveraging its strong commercial capabilities, the Company has in-licensed the rights to distribute additional approved medicines for the China market. Supported by its global clinical development and commercial capabilities, the Company has entered into collaborations with world-leading biopharmaceutical companies such as Amgen Inc. (“Amgen”) and Beijing Novartis Pharma Co., Ltd. (“Novartis”) to develop and commercialize innovative medicines. The Company is committed to advancing best- and first-in-class clinical candidates internally or with like-minded partners to develop impactful and affordable medicines for patients across the globe. Recognizing the importance of clinical trial activities in its industry and the challenges associated with outsourcing to third-party contract research organizations (“CROs”), the Company has built a fully dedicated 3,000+ person clinical team that is largely CRO free, the majority of which are in the Americas, Europe, Australia, Japan and Korea. Basis of presentation and consolidation The accompanying condensed consolidated balance sheet as of June 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023, the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023, and the condensed consolidated statements of shareholders’ equity for the three and six months ended June 30, 2024 and 2023, and the related footnote disclosures are unaudited. The accompanying unaudited interim condensed financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including guidance with respect to interim financial information and in conformity with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation. Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and determining the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates. Recent accounting pronouncements New accounting standards which have not yet been adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact on its financial statements of adopting this guidance. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance. Significant accounting policies For a more complete discussion of the Company’s significant accounting policies and other information, the unaudited interim condensed consolidated financial statements and notes thereto should be read in conjunction with the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2023. There have been no material changes to the Company’s significant accounting policies as of and for the six months ended June 30, 2024, as compared to the significant accounting policies described in the Annual Report.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The Company measures certain financial assets and liabilities at fair value. Fair value is determined based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants, as determined by either the principal market or the most advantageous market. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy, as follows: Level 1 – Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the asset or liability. The Company considers an active market to be one in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis, and considers an inactive market to be one in which there are infrequent or few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. The following tables present the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis using the above input categories as of June 30, 2024 and December 31, 2023: Quoted Price in Active Market for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs As of June 30, 2024 (Level 1) (Level 2) (Level 3) $ $ $ Cash equivalents Money market funds 897,906 — — Prepaid expenses and other current assets: Convertible debt instrument — — 4,968 Other non-current assets (Note 4): Equity securities with readily determinable fair values 1,440 115 — Convertible debt instrument — — 4,773 Total 899,346 115 9,741 Quoted Price in Active Market for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs As of December 31, 2023 (Level 1) (Level 2) (Level 3) $ $ $ Cash equivalents Money market funds 1,052,149 — — Time deposits 42,852 — — Prepaid expenses and other current assets: U.S. Treasury securities 2,600 — — Convertible debt instrument — — 4,668 Other non-current assets (Note 4): Equity securities with readily determinable fair values 3,046 542 — Convertible debt instrument — — 4,215 Total 1,100,647 542 8,883 The Company’s cash equivalents are highly liquid investments with original maturities of 3 months or less. The Company’s investments in available-for-sale debt securities include U.S. Treasury securities. The Company determines the fair value of cash equivalents and available-for-sale debt securities using a market approach based on quoted prices in active markets. The Company’s equity securities carried at fair value consist of holdings in common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (“Leap”), a publicly-traded biotechnology company. The common stock investment is measured and carried at fair value and classified as a Level 1 investment. The warrants to purchase additional shares of common stock are measured using the Black-Scholes option-pricing valuation model and classified as a Level 2 investment. Refer to Note 4, Restricted Cash and Investments for details of the determination of the carrying amount of private equity investments without readily determinable fair values and equity method investments. The Company holds convertible notes issued by private biotech companies. The Company elected the fair value option method of accounting for the convertible notes. Accordingly, the convertible notes are remeasured at fair value on a recurring basis using Level 3 inputs, with any changes in the fair value option recorded in other expense, net. As of June 30, 2024 and December 31, 2023, the fair values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable, and short-term debt approximated their carrying values due to their short-term nature. Long-term bank loans approximate their fair value due to the fact that the related interest rates approximate the rates currently offered by financial institutions for similar debt instrument of comparable maturities.

Collaborative and Licensing Arr

Collaborative and Licensing Arrangements	6 Months Ended
	Jun. 30, 2024
Research and Development [Abstract]
Collaborative and Licensing Arrangements	Collaborative and Licensing Arrangements The Company has entered into collaborative arrangements for the research and development, manufacture and/or commercialization of medicines and drug candidates. To date, these collaborative arrangements have included out-licenses of and options to out-license internally developed products and drug candidates to other parties, in-licenses of products and drug candidates from other parties, and profit- and cost-sharing arrangements. These arrangements may include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing and reimbursement arrangements, royalty payments, and profit sharing. For detailed descriptions of each arrangement, see the Company’s Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission on February 26, 2024. Out-Licensing Arrangements For the three and six months ended June 30, 2024, the Company’s collaboration revenue consisted primarily of revenue generated under the Novartis broad markets agreement. For the three and six months ended June 30, 2023, the Company’s collaboration revenue primarily consisted of the recognition of previously deferred revenue from its former collaboration agreements with Novartis for tislelizumab and ociperlimab. The following table summarizes total collaboration revenue recognized for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Revenue from Collaborators $ $ $ $ Research and development service revenue — 13,563 — 20,380 Right to access intellectual property revenue — 26,248 — 52,497 Other 8,020 1,705 12,754 6,149 Total 8,020 41,516 12,754 79,026 Novartis Tislelizumab Collaboration and License In September 2023, the Company and Novartis agreed to mutually terminate the tislelizumab collaboration and license agreement. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize tislelizumab with no royalty payments due to Novartis. Novartis may continue its ongoing clinical trials and has the ability to conduct future combination trials with tislelizumab subject to BeiGene’s approval. BeiGene agreed to provide Novartis with ongoing clinical supply of tislelizumab to support its clinical trials. Pursuant to the termination agreement, Novartis agreed to provide transition services to the Company to enable key aspects of the tislelizumab development and commercialization plan to proceed without disruption, including manufacturing, regulatory, safety and clinical support. Upon termination of the agreement in September 2023, there were no further performance obligations, and the remaining deferred revenue balance associated with the tislelizumab R&D services was recognized in full. No research and development service collaboration revenue was recognized in connection with the tislelizumab collaboration and license agreement during the three and six months ended June 30, 2024 due to termination of the agreement in 2023. The following table summarizes revenue recognized related to the sale of tislelizumab clinical supply to Novartis for the three and six months ended June 30, 2024 and research and development service revenue recognized for the three and six months ended June 30, 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 11,770 — 16,796 Other (1) 2,113 1,344 2,113 5,013 Total 2,113 13,114 2,113 21,809 (1) Represents revenue recognized on final shipment of tislelizumab clinical supply to Novartis in conjunction with the former collaboration. Ociperlimab Option, Collaboration and License Agreement and China Broad Market Development Agreement In July 2023, the Company and Novartis mutually agreed to terminate the ociperlimab option, collaboration and license agreement. Pursuant to the termination agreement, the Company regained full, global rights to develop, manufacture and commercialize ociperlimab. Upon termination the Company had no further performance obligations under the collaboration, and all remaining deferred revenue balances were recognized in full. The China broad markets agreement remains in place. The following table summarizes collaboration revenue recognized in connection with the China broad markets agreement for the three and six months ended June 30, 2024 and the terminated ociperlimab option, collaboration and license agreement for the three and six months ended June 30, 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 1,792 — 3,583 Right to access intellectual property revenue — 26,248 — 52,497 China broad markets agreement 4,154 1,861 8,501 2,636 Total 4,154 29,901 8,501 58,716 In-Licensing Arrangements - Commercial Amgen During the three and six months ended June 30, 2024 and 2023, the Company recorded the following amounts related to its collaboration arrangement with Amgen. For a detailed description of the arrangement and related rights and obligation, see the Company’s Form 10-K for the year ended December 31, 2023 filed on February 26, 2024. Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development expense 22,482 5,457 35,966 23,274 Amortization of research and development cost share liability 21,903 5,271 35,039 22,669 Total amount due to Amgen for BeiGene’s portion of the development funding 44,385 10,728 71,005 45,943 As of June 30, 2024 $ Remaining portion of development funding cap 412,647 As of June 30, 2024 and December 31, 2023, the research and development cost share liability recorded in the Company’s balance sheet was as follows: As of June 30, December 31, 2024 2023 $ $ Research and development cost share liability, current portion 84,615 68,004 Research and development cost share liability, non-current portion 119,012 170,662 Total research and development cost share liability 203,627 238,666 The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three and six months ended June 30, 2024 and 2023 as follows: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Cost of sales - product 9,590 4,011 18,159 1,184 Research and development (439) (1,769) (1,144) 1,311 Selling, general and administrative (21,100) (17,552) (39,253) (29,388) Total (11,949) (15,310) (22,238) (26,893) The Company purchases commercial inventory from Amgen to distribute in China. Inventory purchases amounted to $47,653 and $109,879 during the three and six months ended June 30, 2024, respectively, and $20,146 and $39,277 during the three and six months ended June 30, 2023, respectively. Net amounts payable to Amgen was $66,824 and $55,474 as of June 30, 2024 and December 31, 2023, respectively. In-Licensing Arrangements - Development The Company has in-licensed the rights to develop, manufacture and, if approved, commercialize multiple development stage drug candidates globally or in specific territories. These arrangements typically include non-refundable upfront payments, contingent obligations for potential development, regulatory and commercial performance milestone payments, cost-sharing arrangements, royalty payments, and profit sharing. Upfront and milestone payments incurred under these arrangements for the three and six months ended June 30, 2024 and 2023 are set forth below. All upfront and development milestones were expensed to research and development expense. Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Payments due to collaboration partners Classification $ $ $ $ Upfront payments Research and development expense — — 27 — Development milestones incurred Research and development expense 11,500 — 46,500 — Total 11,500 — 46,527 —

Restricted Cash and Investments

Restricted Cash and Investments	6 Months Ended
	Jun. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Restricted Cash and Investments	Restricted Cash and Investments Restricted Cash The Company’s restricted cash primarily consists of RMB-denominated cash deposits held in designated bank accounts for collateral for letters of credit. The Company classifies restricted cash as current or non-current based on the term of the restriction. Restricted cash as of June 30, 2024 and December 31, 2023 was as follows: As of June 30, December 31, 2024 2023 $ $ Short-term restricted cash 23,155 11,473 Long-term restricted cash 2,121 2,711 Total 25,276 14,184 In addition to the restricted cash balances above, the Company is required by the PRC securities law to use the proceeds from its offering on the STAR Market of the Shanghai Stock Exchange (the “STAR Offering”) in strict compliance with the planned uses as disclosed in the PRC prospectus as well as those disclosed in the Company’s proceeds management policy approved by the board of directors. As of June 30, 2024, the Company had cash remaining related to the STAR Offering proceeds of $856,722. Investments in Equity Securities The following table summarizes the Company’s investments in equity securities: As of June 30, December 31, 2024 2023 $ $ Equity securities with readily determinable fair values (1) Fair value of Leap common stock 1,440 3,046 Fair value of Leap warrants 115 542 Equity securities without readily determinable fair values Pi Health, Inc. (2) 40,798 — Other 54,865 55,860 Equity-method investments 37,780 25,981 Total 134,998 85,429 (1) Represents common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (“Leap”). The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other expense, net. (2) In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $38,063. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $40,798 and cash consideration of $1,000. The transaction resulted in a pre-tax gain of $3,735 recorded within other expense, net during the six months ended June 30, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company’s continuing operations. The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other expense, net for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Equity securities with readily determinable fair values (621) 470 (2,033) (636) Equity securities without readily determinable fair values — — (797) 1,081 Equity-method investments (4,017) (2,480) (4,873) (2,624)

Inventories, Net

Inventories, Net	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net The Company’s inventories, net consisted of the following: As of June 30, December 31, 2024 2023 $ $ Raw materials 143,655 148,772 Work in process 59,499 39,098 Finished goods 240,106 228,252 Total inventories, net 443,260 416,122

Property, Plant and Equipment,

Property, Plant and Equipment, Net	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment, Net	Property, Plant and Equipment, Net Property, plant and equipment, net are recorded at cost and consisted of the following: As of June 30, December 31, 2024 2023 $ $ Land 65,485 65,485 Building 304,854 231,656 Manufacturing equipment 227,146 186,856 Laboratory equipment 216,673 205,349 Leasehold improvement 60,382 60,124 Software, electronics and office equipment 67,649 83,281 Property, plant and equipment, at cost 942,189 832,751 Less: accumulated depreciation (289,114) (249,212) Construction in progress 863,416 740,615 Property, plant and equipment, net 1,516,491 1,324,154 The Company has made a significant investment in its newly opened manufacturing and R&D center in Hopewell, New Jersey. As of June 30, 2024, the Company had land and construction in progress of $677,126 related to the Hopewell facility, the majority of which will be put into service in the second half of 2024. In March 2024, the Company acquired a land use right and the facility currently being constructed on the land for $73,373. The Company plans to complete the construction of the facility and build a research and development center on the land. Based on the relative fair values of the land use right and construction in progress, $28,699 of the total purchase price was allocated to the land use right and $44,674 was allocated to the construction in progress. In May 2024, the Company acquired additional construction in progress in connection with the properties for $22,637. As of June 30, 2024, title of the land use right was being transitioned to the Company. As such, the purchase price allocated to the land use right was recorded as a long-term prepaid as of June 30, 2024 and will be transferred to operating lease right-of-use asset upon the closing of the transaction. Depreciation expense was $23,754 and $47,864 for the three and six months ended June 30, 2024, respectively, and $21,307 and $40,332 for the three and six months ended June 30, 2023, respectively.

Intangible Assets

Intangible Assets	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Intangible assets as of June 30, 2024 and December 31, 2023 are summarized as follows: As of June 30, 2024 December 31, 2023 Gross Gross carrying Accumulated Intangible carrying Accumulated Intangible amount amortization assets, net amount amortization assets, net $ $ $ $ $ $ Finite-lived intangible assets: Developed products 63,098 (10,054) 53,044 64,274 (7,807) 56,467 Other 8,987 (8,316) 671 8,987 (8,316) 671 Total finite-lived intangible assets 72,085 (18,370) 53,715 73,261 (16,123) 57,138 Developed products represent post-approval milestone payments under license and commercialization agreements. The Company is amortizing the developed products over the remainder of the respective product patent or the term of the commercialization agreements. Amortization expense for developed products is included in cost of sales - product in the accompanying consolidated statements of operations. Amortization expense for other intangible assets is included in operating expenses in the accompanying consolidated statements of operations. The weighted-average life for each finite-lived intangible assets is approximately 12 years. Amortization expense was as follows: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Amortization expense - Cost of sales - product 1,177 840 2,360 1,639 Amortization expense - Operating expense — 188 — 375 Total 1,177 1,028 2,360 2,014 Estimated amortization expense for each of the five succeeding years and thereafter, as of June 30, 2024 is as follows: Year Ending December 31, Cost of Sales - Product Operating Expenses Total $ $ $ 2024 (remainder of year) 2,348 67 2,415 2025 4,696 67 4,763 2026 4,696 67 4,763 2027 4,696 67 4,763 2028 4,696 67 4,763 2029 and thereafter 31,912 336 32,248 Total 53,044 671 53,715

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income tax expense was $14,485 and $22,209 for the three and six months ended June 30, 2024, respectively, and $13,674 and $25,166 for the three and six months ended June 30, 2023, respectively. The income tax expense for the three and six months ended June 30, 2024 and 2023 was primarily attributable to current U.S. tax expense determined after other special tax deductions and research and development tax credits, current Switzerland tax expense based on year to date earnings, and current China tax expense due to certain non-deductible expenses. On a quarterly basis, the Company evaluates the realizability of deferred tax assets by jurisdiction and assesses the need for a valuation allowance. In assessing the realizability of deferred tax assets, the Company considers historical profitability, evaluation of scheduled reversals of deferred tax liabilities, projected future taxable income and tax-planning strategies. Valuation allowances have been provided on deferred tax assets where, based on all available evidence, it was considered more likely than not that some portion or all of the recorded deferred tax assets will not be realized in future periods. After consideration of all positive and negative evidence, as of June 30, 2024, the Company will maintain a full valuation allowance against its net deferred tax assets. As of June 30, 2024, the Company had gross unrecognized tax benefits of $15,804. The Company does not anticipate that the amount of existing unrecognized tax benefits will significantly change within the next 12 months. The Company’s reserve for uncertain tax positions increased by $880 and $1,540 in the three and six months ended June 30, 2024 primarily due to U.S. federal and state tax credits and incentives.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	6 Months Ended
	Jun. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Supplemental Balance Sheet Information	Supplemental Balance Sheet Information Prepaid expenses and other current assets consist of the following: As of June 30, December 31, 2024 2023 $ $ Prepaid research and development costs 68,234 60,476 Prepaid manufacturing cost 32,986 42,066 Prepaid taxes 32,193 37,320 Other receivables 58,776 37,859 Short-term restricted cash 23,155 11,473 Prepaid insurance 10,158 8,872 Other current assets 48,156 59,399 Total 273,658 257,465 Other non-current assets consist of the following: As of June 30, December 31, 2024 2023 $ $ Prepayment of property and equipment (1) 34,335 4,144 Prepaid supply cost 12,487 18,122 Prepaid VAT 2,602 2,546 Rental deposits and other 8,002 8,195 Long-term restricted cash 2,121 2,711 Long-term investments (Note 4) 139,771 89,644 Total 199,318 125,362 (1) Includes payment for acquired land use right in Shanghai, China that was in the process of being transitioned to the Company as of June 30, 2024 (See Note 6). Accrued expenses and other payables consist of the following: As of June 30, December 31, 2024 2023 $ $ Compensation related 167,960 217,803 External research and development activities related 133,412 162,969 Commercial activities 70,641 87,572 Individual income tax and other taxes 48,466 30,083 Sales rebates and returns related 173,263 139,936 Other 52,796 55,368 Total 646,538 693,731 Other long-term liabilities consist of the following: As of June 30, December 31, 2024 2023 $ $ Deferred government grant income 32,021 34,204 Pension liability 14,639 14,995 Asset retirement obligation 1,101 1,127 Other 3,772 484 Total 51,533 50,810

Debt

Debt	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Debt	Debt The following table summarizes the Company’s short-term and long-term debt obligations as of June 30, 2024 and December 31, 2023: Lender Line of Credit Term Maturity Date Interest Rate As of June 30, 2024 December 31, 2023 $ RMB $ RMB China Construction Bank RMB580,000 9-year April 4, 2027 (1) 15,136 110,000 14,089 100,000 China Merchants Bank RMB350,000 9-year January 20, 2029 (2) 8,649 62,857 8,856 62,857 China Merchants Bank RMB378,000 9-year November 8, 2029 (3) 6,848 49,765 5,636 40,000 China Merchants Bank $380,000 1-year (4) 380,000 2,761,628 300,000 2,129,321 China Minsheng Bank $150,000 1-year December 19, 2024 7.3% 150,000 1,090,116 150,000 1,064,660 China Industrial Bank RMB 675,000 364-day March 27, 2025 (5) 92,880 675,000 — — China Merchants Bank RMB 400,000 1-year June 5, 2025 3.0% 55,040 400,000 56,356 400,000 HSBC Bank RMB 340,000 1-year May 5, 2025 (6) 46,784 340,000 47,903 340,000 China Industrial Bank RMB 200,000 1-year May 29, 2024 — — — 28,177 200,000 Shanghai Pudong Development Bank RMB 700,000 1-year (7) 2.9% 96,320 700,000 49,312 350,000 Other short-term debt (8) — — 28,037 199,000 Total short-term debt 851,657 6,189,366 688,366 4,885,838 China Construction Bank RMB580,000 9-year April 4, 2027 (1) 49,536 360,000 59,174 420,000 China Merchants Bank RMB350,000 9-year January 20, 2029 (2) 32,434 235,714 37,638 267,143 China Merchants Bank RMB378,000 9-year November 8, 2029 (3) 37,253 270,735 42,337 300,500 China CITIC Bank RMB480,000 10-year July 28, 2032 (9) 66,048 480,000 58,469 415,000 Total long-term bank loans 185,271 1,346,449 197,618 1,402,643 (1) The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 4.2% as of June 30, 2024. The loan is secured by BeiGene Guangzhou Factory’s property ownership certificate. The Company repaid $6,886 (RMB50,000) during the six months ended June 30, 2024. (2) The outstanding borrowings bear floating interest rates benchmarking against prevailing interest rates of certain PRC financial institutions. The loan interest rate was 3.7% as of June 30, 2024. The loan is secured by Guangzhou Factory’s second land use right and certain fixed assets in the second phase of the Guangzhou manufacturing facility’s build out. The Company repaid $4,362 (RMB31,429) during the six months ended June 30, 2024. (3) The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.9% as of June 30, 2024. The loan is secured by fixed assets placed into service upon completion of the third phase of the Guangzhou manufacturing facility’s build out. The Company repaid $2,772 (RMB20,000) during the six months ended June 30, 2024. (4) The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 7.2% as of June 30, 2024. $300,000 of the borrowings matures on December 25, 2024, and $80,000 matures on January 27, 2025. (5) The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 2.6% as of June 30, 2024. (6) The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 5.7% as of June 30, 2024. (7) $48,160 (RMB350,000) of the outstanding borrowings matures on November 21, 2024 and March 19, 2025, respectively. (8) During the two years ended December 31, 2023, the Company entered into short-term working capital loans with China Industrial Bank and China Merchants Bank to borrow up to RMB875,000 in aggregate. The Company repaid $27,476 (RMB199,000) during the six months ended June 30, 2024. (9) In July 2022, the Company entered into a 10-year bank loan agreement with China CITIC Bank to borrow up to RMB480,000 at a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The Company drew down $9,053 (RMB65,000) during the six months ended June 30, 2024. The weighted average loan interest rate was 3.9% as of June 30, 2024. The loan is secured by BeiGene Suzhou Co., Ltd.’s property ownership certificate of the small molecule manufacturing campus in Suzhou, China. The Company has numerous financial and non-financial covenants on its debt obligations with various banks and other lenders. Some of these covenants include cross-default provisions that could require acceleration of repayment of loans in the event of default. However, the Company’s debt is primarily short-term in nature. Any acceleration would be a matter of months but may impact the Company’s ability to refinance debt obligations if an event of default occurs. As of June 30, 2024, the Company was in compliance with all covenants of its material debt agreements. Interest Expense

Product Revenue

Product Revenue	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Product Revenue	Product Revenue The Company’s product revenue is primarily derived from the sale of its internally developed products BRUKINSA in the U.S., Europe, China, and other regions, and tislelizumab in China; XGEVA ® , BLINCYTO ® and KYPROLIS ® in China under a license from Amgen; and POBEVCY ® in China under a license from Bio-Thera. The table below presents the Company’s net product sales for the three and six months ended June 30, 2024 and 2023. Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Product revenue – gross 1,167,155 667,328 2,111,619 1,176,933 Less: Rebates and sales returns (246,009) (113,583) (443,555) (212,897) Product revenue – net 921,146 553,745 1,668,064 964,036 The following table disaggregates net product sales by product for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ BRUKINSA ® 637,399 308,276 1,125,914 519,658 Tislelizumab 158,410 149,464 303,687 264,314 XGEVA ® 55,054 23,968 98,435 44,165 BLINCYTO ® 19,131 14,578 33,497 25,524 KYPROLIS ® 15,936 11,052 30,047 15,995 POBEVCY ® 11,572 13,438 28,205 27,764 REVLIMID ® 9,133 21,847 21,366 45,005 Other 14,511 11,122 26,913 21,611 Total product revenue – net 921,146 553,745 1,668,064 964,036 The following table presents the roll-forward of accrued sales rebates and returns for the six months ended June 30, 2024 and 2023: Six Months Ended June 30, 2024 2023 $ $ Balance at beginning of the period 139,936 41,817 Accrual 443,555 212,897 Payments (410,228) (169,123) Balance at end of the period 173,263 85,591

Loss Per Share

Loss Per Share	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Loss Per Share	Loss Per Share The following table reconciles the numerator and denominator in the computations of basic and diluted loss per share: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Numerator: Net loss (120,405) (381,137) (371,555) (729,568) Denominator: Weighted average shares outstanding for computing basic and diluted loss per share 1,361,082,567 1,360,224,377 1,358,315,145 1,357,211,308 Loss per share (0.09) (0.28) (0.27) (0.54) For the three and six months ended June 30, 2024 and 2023, the computation of basic loss per share using the two-class method was not applicable as the Company was in a net loss position, and the effects of all share options, restricted shares, restricted share units and ESPP shares were excluded from the calculation of diluted loss per share, as their effect would have been anti-dilutive.

Share-Based Compensation Expens

Share-Based Compensation Expense	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation Expense	Share-Based Compensation Expense 2016 Share Option and Incentive Plan In January 2016, in connection with the Company’s initial public offering (“IPO”) on the Nasdaq Stock Market, the board of directors and shareholders of the Company approved the 2016 Share Option and Incentive Plan (the “2016 Plan”), which became effective in February 2016. The Company initially reserved 65,029,595 ordinary shares for the issuance of awards under the 2016 Plan, plus any shares available under the 2011 Option Plan (the “2011 Plan”), and not subject to any outstanding options as of the effective date of the 2016 Plan, along with underlying share awards under the 2011 Plan that are cancelled or forfeited without issuance of ordinary shares. In December 2018, the shareholders approved a second amended and restated 2016 Plan to increase the number of shares authorized for issuance by 38,553,159 ordinary shares, as well as amend the cap on annual compensation to independent directors and make other changes. In June 2020, the shareholders approved an amendment to the 2016 Plan to increase the number of shares authorized for issuance by 57,200,000 ordinary shares and to extend the term of the plan through April 13, 2030. The number of shares available for issuance under the 2016 Plan is subject to adjustment in the event of a share split, share dividend or other change in the Company’s capitalization. In order to continue to provide incentive opportunities under the 2016 Plan, the Board of Directors and shareholders of the Company approved another amendment to the 2016 Plan (the “Amendment No. 2”), which became effective as of June 22, 2022, to increase the number of authorized shares available for issuance under the 2016 Plan by 66,300,000 ordinary shares. In June 2024, the shareholders of the Company approved a third amended and restated 2016 Plan (the “Amended 2016 Plan”) to comply with certain amendments of Chapter 17 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “HK Listing Rules”) and to increase the number of shares available for issuance thereunder by 92,820,000 ordinary shares. As of June 30, 2024, ordinary shares cancelled or forfeited under the 2011 Plan that were carried over to the Amended 2016 Plan totaled 5,166,848. During the six months ended June 30, 2024, the Company granted options for 8,394,737 ordinary shares, restricted share units for 42,514,355 ordinary shares, and performance share units for 2,287,402 ordinary shares under the Amended 2016 Plan. As of June 30, 2024, options, restricted share units, and performance share units for ordinary shares outstanding under the Amended 2016 Plan totaled 67,378,462, 87,422,244, and 2,287,402, respectively. As of June 30, 2024, share-based awards to acquire 82,059,496 ordinary shares were available for future grant under the Amended 2016 Plan. 2018 Employee Share Purchase Plan In June 2018, the shareholders of the Company approved the 2018 Employee Share Purchase Plan (the “ESPP”). Initially, 3,500,000 ordinary shares of the Company were reserved for issuance under the ESPP. In August 2018, in connection with the Company’s listing on the Hong Kong Stock Exchange, the board of directors approved an amended and restated ESPP to remove an “evergreen” share replenishment provision originally included in the plan and implemented other changes required by the HK Listing Rules. In December 2018, the shareholders of the Company approved a second amended and restated ESPP to increase the number of shares authorized for issuance by 3,855,315 ordinary shares to 7,355,315 ordinary shares. In June 2019, the board of directors adopted an amendment to revise the eligibility criteria for enrollment in the plan. In June 2021, the board of directors of the Company adopted the third amended and restated ESPP to include certain technical amendments under U.S. tax rules and to consolidate the changes in the prior amendment, effective on September 1, 2021. In June 2024, the shareholders approved a fourth amended and restated ESPP (the “Amended ESPP”) to comply with certain amendments of Chapter 17 of the HK Listing Rules and to increase the number of shares available for sale thereunder by 5,070,000 shares. The Amended ESPP allows eligible employees to purchase the Company’s ordinary shares (including in the form of ADSs) at the end of each offering period, which will generally be six months, at a 15% discount to the market price of the Company’s ADSs at the beginning or the end of each offering period, whichever is lower, using funds deducted from their payroll during the offering period. Eligible employees are able to authorize payroll deductions of up to 10% of their eligible earnings, subject to applicable limitations. As of June 30, 2024, 5,989,678 ordinary shares were available for future issuance under the Amended ESPP. The following tables summarizes the shares issued under the ESPP: Market Price 1 Purchase Price 2 Issuance Date Number of Ordinary Shares Issued ADS Ordinary ADS Ordinary Proceeds February 29, 2024 1,021,397 $ 165.65 $ 12.74 $ 140.80 $ 10.83 $ 11,063 August 31, 2023 794,144 $ 207.55 $ 15.97 $ 176.42 $ 13.57 $ 10,777 February 28, 2023 930,582 $ 171.10 $ 13.16 $ 145.44 $ 11.19 $ 10,414 1 The market price is the lower of the closing price on the Nasdaq Stock Market on the issuance date or the offering date, in accordance with the terms of the ESPP. 2 The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP. Share-Based Compensation Expense The following table summarizes total share-based compensation expense recognized for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development 55,406 45,948 93,451 79,976 Selling, general and administrative 75,288 57,381 125,957 98,741 Total 130,694 103,329 219,408 178,717

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The movement of accumulated other comprehensive loss was as follows: Unrealized Foreign Currency Gains/(Losses) on Pension Translation Available-for-Sale Liability Adjustments Securities Adjustments Total $ $ $ $ Balance as of December 31, 2023 (87,987) 35 (11,494) (99,446) Other comprehensive (loss) income before reclassifications (41,399) (35) — (41,434) Amounts reclassified from accumulated other comprehensive income (loss) — — 406 406 Net-current period other comprehensive (loss) income (41,399) (35) 406 (41,028) Balance as of June 30, 2024 (129,386) — (11,088) (140,474)

Shareholders_ Equity

Shareholders’ Equity	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Shareholders’ Equity	Shareholders’ Equity BMS Settlement On August 1, 2023, the Company entered into a Settlement and Termination Agreement (the “Settlement Agreement”) with BMS-Celgene and certain of its affiliates relating to the termination of the parties’ ongoing contractual relationships, the previously-disclosed ongoing arbitration proceeding concerning ABRAXANE ®

Restricted Net Assets

Restricted Net Assets	6 Months Ended
	Jun. 30, 2024
Restricted Net Assets Disclosure [Abstract]
Restricted Net Assets	Restricted Net Assets The Company’s ability to pay dividends may depend on the Company receiving distributions of funds from its PRC subsidiaries. Relevant PRC statutory laws and regulations permit payments of dividends by the Company’s PRC subsidiaries only out of the subsidiary’s retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. The results of operations reflected in the condensed consolidated financial statements prepared in accordance with GAAP differ from those reflected in the statutory financial statements of the Company’s PRC subsidiaries. In accordance with the company law of the PRC, a domestic enterprise is required to provide statutory reserves of at least 10% of its annual after-tax profit until such reserve has reached 50% of its respective registered capital based on the enterprise’s PRC statutory accounts. A domestic enterprise is also required to provide discretionary surplus reserve, at the discretion of the board of directors, from the profits determined in accordance with the enterprise’s PRC statutory accounts. The aforementioned reserves can only be used for specific purposes and are not distributable as cash dividends. The Company’s PRC subsidiaries were established as domestic enterprises and therefore are subject to the above-mentioned restrictions on distributable profits. As a result of these PRC laws and regulations, including the requirement to make annual appropriations of at least 10% of after-tax income and set aside as general reserve fund prior to payment of dividends, the Company’s PRC subsidiaries are restricted in their ability to transfer a portion of their net assets to the Company.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Purchase Commitments As of June 30, 2024, the Company had non-cancellable purchase commitments amounting to $120,366, of which $28,822 related to minimum purchase requirements for supply purchased from contract manufacturing organizations and $91,544 related to binding purchase obligations of inventory from Amgen. The Company does not have any minimum purchase requirements for inventory from Amgen. Capital Commitments The Company had capital commitments amounting to $62,576 for the acquisition of property, plant and equipment as of June 30, 2024, related to various facilities across the globe, including the manufacturing and clinical R&D campus in Hopewell, New Jersey. Co-Development Funding Commitment Under the Amgen Collaboration Agreement, the Company is responsible for co-funding global development costs for the Amgen oncology pipeline assets up to a total cap of $1,250,000. The Company is funding its portion of the co-development costs by contributing cash and development services. As of June 30, 2024, the Company’s remaining co-development funding commitment was $412,647. Funding Commitment The Company had committed capital related to two equity-method investments in the amount of $15,054. As of June 30, 2024, the remaining capital commitment was $8,154 and is expected to be paid from time to time over the investment period.

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information The Company operates in one segment: pharmaceutical products. Its chief operating decision maker is the Chief Executive Officer, who makes operating decisions, assesses performance and allocates resources on a consolidated basis. The Company’s long-lived assets are primarily located in the U.S. and the PRC. Net product revenues by geographic area are based upon the location of the customer, and net collaboration revenue is recorded in the jurisdiction in which the related income is expected to be sourced from. Total revenues by geographic area are presented as follows: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ U.S. - total revenue 481,430 252,347 832,886 416,830 Product revenue 479,365 223,539 830,821 362,307 Collaboration revenue 2,065 28,808 2,065 54,523 China- total revenue 352,070 295,783 672,446 543,464 Product revenue 347,112 293,922 662,774 540,828 Collaboration revenue 4,958 1,861 9,672 2,636 Europe- total revenue 82,389 37,169 149,249 67,690 Product revenue 81,392 26,322 148,232 45,823 Collaboration revenue 997 10,847 1,017 21,867 Rest of world- total revenue 13,277 9,962 26,237 15,078 Product revenue 13,277 9,962 26,237 15,078 Collaboration revenue — — — — Total Revenue 929,166 595,261 1,680,818 1,043,062

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net loss	$ (120,405)	$ (251,150)	$ (381,137)	$ (348,431)	$ (371,555)	$ (729,568)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	6 Months Ended
	Jun. 30, 2024 shares	Jun. 30, 2024 shares
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		Name ( Title ) Action Taken ( Date of Action ) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities Dr. Xiaobin Wu (President, Chief Operating Officer) Adoption (May 13, 2024) Rule 10b5-1 trading arrangement Sale September 5, 2025 Restricted Stock Units (“RSU”) and stock options equaling to up to 218,240 American Depositary Shares (“ADSs”) less any shares sold pursuant to Dr. Wu’s prior 10b5-1 plan, which expired on May 12, 2024, but prior to this trading plan’s selling start date. Julia Wang (Former Chief Financial Officer) Adoption (May 22, 2024) Rule 10b5-1 trading arrangement Sale August 29, 2025 78,727 ADSs plus an additional number of ADSs subject to RSUs equal to the net number of shares resulting from applicable RSU vestings after sell-to-cover for withholding tax. Dr. Lai Wang (Global Head of R&D) Adoption (June 13, 2024) Rule 10b5-1 trading arrangement Sale September 12, 2025 20,000 ADSs
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Dr. Xiaobin Wu [Member]
Trading Arrangements, by Individual
Name	Dr. Xiaobin Wu
Title	President, Chief Operating Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 13, 2024
Expiration Date	September 5, 2025
Arrangement Duration	480 days
Aggregate Available	218,240	218,240
Julia Wang [Member]
Trading Arrangements, by Individual
Name	Julia Wang
Title	Former Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	May 22, 2024
Expiration Date	August 29, 2025
Arrangement Duration	464 days
Aggregate Available	78,727	78,727
Dr. Lai Wang [Member]
Trading Arrangements, by Individual
Name	Dr. Lai Wang
Title	Global Head of R&D
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	June 13, 2024
Expiration Date	September 12, 2025
Arrangement Duration	456 days
Aggregate Available	20,000	20,000

Description of Business, Basi_2

Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation and consolidation	Basis of presentation and consolidation The accompanying condensed consolidated balance sheet as of June 30, 2024, the condensed consolidated statements of operations and comprehensive loss for the three and six months ended June 30, 2024 and 2023, the condensed consolidated statements of cash flows for the six months ended June 30, 2024 and 2023, and the condensed consolidated statements of shareholders’ equity for the three and six months ended June 30, 2024 and 2023, and the related footnote disclosures are unaudited. The accompanying unaudited interim condensed financial statements were prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), including guidance with respect to interim financial information and in conformity with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”). The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all normal recurring adjustments, necessary to present a fair statement of the results for the interim periods presented. Results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. The unaudited interim condensed consolidated financial statements include the financial statements of the Company and its subsidiaries. All significant intercompany transactions and balances between the Company and its subsidiaries are eliminated upon consolidation.
Use of estimates	Use of estimates The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and determining the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates.
Recent accounting pronouncements	Recent accounting pronouncements New accounting standards which have not yet been adopted In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This update requires disclosure of incremental segment information on an annual and interim basis. This update is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact on its financial statements of adopting this guidance. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This update requires that public entities on an annual basis, (1) in the rate reconciliation, disclose specific categories and provide additional information for reconciling items that meet a quantitative threshold; (2) about income taxes paid, disclose the amount of income taxes paid (net of refunds received) disaggregated by federal, state, and foreign taxes and by individual jurisdiction in which income taxes paid (net of refunds received) is equal to or greater than 5 percent of total income taxes paid (net of refunds received); and (3) disclose income (or loss) from continuing operations before income tax expense (or benefit) disaggregated between domestic and foreign and income tax expense (or benefit) disaggregated by federal, state, and foreign. This update is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. This guidance should be applied on a prospective basis. Retrospective application is permitted. The Company is currently evaluating the impact on its financial statements of adopting this guidance.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables present the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis using the above input categories as of June 30, 2024 and December 31, 2023: Quoted Price in Active Market for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs As of June 30, 2024 (Level 1) (Level 2) (Level 3) $ $ $ Cash equivalents Money market funds 897,906 — — Prepaid expenses and other current assets: Convertible debt instrument — — 4,968 Other non-current assets (Note 4): Equity securities with readily determinable fair values 1,440 115 — Convertible debt instrument — — 4,773 Total 899,346 115 9,741 Quoted Price in Active Market for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs As of December 31, 2023 (Level 1) (Level 2) (Level 3) $ $ $ Cash equivalents Money market funds 1,052,149 — — Time deposits 42,852 — — Prepaid expenses and other current assets: U.S. Treasury securities 2,600 — — Convertible debt instrument — — 4,668 Other non-current assets (Note 4): Equity securities with readily determinable fair values 3,046 542 — Convertible debt instrument — — 4,215 Total 1,100,647 542 8,883

Collaborative and Licensing A_2

Collaborative and Licensing Arrangements (Tables)	6 Months Ended
	Jun. 30, 2024
Research and Development [Abstract]
Schedule of Net Product Sales	The following table summarizes total collaboration revenue recognized for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Revenue from Collaborators $ $ $ $ Research and development service revenue — 13,563 — 20,380 Right to access intellectual property revenue — 26,248 — 52,497 Other 8,020 1,705 12,754 6,149 Total 8,020 41,516 12,754 79,026 Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 11,770 — 16,796 Other (1) 2,113 1,344 2,113 5,013 Total 2,113 13,114 2,113 21,809 (1) Represents revenue recognized on final shipment of tislelizumab clinical supply to Novartis in conjunction with the former collaboration. The following table summarizes collaboration revenue recognized in connection with the China broad markets agreement for the three and six months ended June 30, 2024 and the terminated ociperlimab option, collaboration and license agreement for the three and six months ended June 30, 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 1,792 — 3,583 Right to access intellectual property revenue — 26,248 — 52,497 China broad markets agreement 4,154 1,861 8,501 2,636 Total 4,154 29,901 8,501 58,716 The table below presents the Company’s net product sales for the three and six months ended June 30, 2024 and 2023. Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Product revenue – gross 1,167,155 667,328 2,111,619 1,176,933 Less: Rebates and sales returns (246,009) (113,583) (443,555) (212,897) Product revenue – net 921,146 553,745 1,668,064 964,036 The following table disaggregates net product sales by product for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ BRUKINSA ® 637,399 308,276 1,125,914 519,658 Tislelizumab 158,410 149,464 303,687 264,314 XGEVA ® 55,054 23,968 98,435 44,165 BLINCYTO ® 19,131 14,578 33,497 25,524 KYPROLIS ® 15,936 11,052 30,047 15,995 POBEVCY ® 11,572 13,438 28,205 27,764 REVLIMID ® 9,133 21,847 21,366 45,005 Other 14,511 11,122 26,913 21,611 Total product revenue – net 921,146 553,745 1,668,064 964,036
Schedule of Collaboration Agreements	Amounts recorded related to the Company’s portion of the co-development funding on the pipeline assets for the three and six months ended June 30, 2024 and 2023 were as follows: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development expense 22,482 5,457 35,966 23,274 Amortization of research and development cost share liability 21,903 5,271 35,039 22,669 Total amount due to Amgen for BeiGene’s portion of the development funding 44,385 10,728 71,005 45,943 As of June 30, 2024 $ Remaining portion of development funding cap 412,647 As of June 30, 2024 and December 31, 2023, the research and development cost share liability recorded in the Company’s balance sheet was as follows: As of June 30, December 31, 2024 2023 $ $ Research and development cost share liability, current portion 84,615 68,004 Research and development cost share liability, non-current portion 119,012 170,662 Total research and development cost share liability 203,627 238,666
Schedule of Amounts and Classification of Reimbursement Expense	The total reimbursement paid under the commercial profit-sharing agreement for product sales is classified in the income statement for the three and six months ended June 30, 2024 and 2023 as follows: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Cost of sales - product 9,590 4,011 18,159 1,184 Research and development (439) (1,769) (1,144) 1,311 Selling, general and administrative (21,100) (17,552) (39,253) (29,388) Total (11,949) (15,310) (22,238) (26,893)
Schedule of Payments Due to Collaboration Partners	Upfront and milestone payments incurred under these arrangements for the three and six months ended June 30, 2024 and 2023 are set forth below. All upfront and development milestones were expensed to research and development expense. Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Payments due to collaboration partners Classification $ $ $ $ Upfront payments Research and development expense — — 27 — Development milestones incurred Research and development expense 11,500 — 46,500 — Total 11,500 — 46,527 —

Restricted Cash and Investmen_2

Restricted Cash and Investments (Tables)	6 Months Ended
	Jun. 30, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of Restrictions on Cash and Cash Equivalents	The Company classifies restricted cash as current or non-current based on the term of the restriction. Restricted cash as of June 30, 2024 and December 31, 2023 was as follows: As of June 30, December 31, 2024 2023 $ $ Short-term restricted cash 23,155 11,473 Long-term restricted cash 2,121 2,711 Total 25,276 14,184
Schedule of Equity Method Investments	The following table summarizes the Company’s investments in equity securities: As of June 30, December 31, 2024 2023 $ $ Equity securities with readily determinable fair values (1) Fair value of Leap common stock 1,440 3,046 Fair value of Leap warrants 115 542 Equity securities without readily determinable fair values Pi Health, Inc. (2) 40,798 — Other 54,865 55,860 Equity-method investments 37,780 25,981 Total 134,998 85,429 (1) Represents common stock and warrants to purchase additional shares of common stock of Leap Therapeutics, Inc. (“Leap”). The Company measures the investment in the common stock and warrants at fair value, with changes in fair value recorded to other expense, net. (2) In the first quarter of 2024, the Company divested the net assets comprising substantially all of its Pi Health business with a carrying value of $38,063. The consideration received for the divestiture consisted of preferred stock in a newly formed entity, Pi Health, Inc., with a fair value of $40,798 and cash consideration of $1,000. The transaction resulted in a pre-tax gain of $3,735 recorded within other expense, net during the six months ended June 30, 2024. The Company will account for its investment prospectively as a private equity security without a readily determinable fair value and the divestiture is not treated as a discontinued operation in the Statement of Operations and therefore the historical results of operations of the Pi Health business will remain in the Company’s continuing operations. The following table summarizes unrealized (losses) gains related to investments in equity securities recorded in other expense, net for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Equity securities with readily determinable fair values (621) 470 (2,033) (636) Equity securities without readily determinable fair values — — (797) 1,081 Equity-method investments (4,017) (2,480) (4,873) (2,624)

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	The Company’s inventories, net consisted of the following: As of June 30, December 31, 2024 2023 $ $ Raw materials 143,655 148,772 Work in process 59,499 39,098 Finished goods 240,106 228,252 Total inventories, net 443,260 416,122

Property, Plant and Equipment_2

Property, Plant and Equipment, Net (Tables)	6 Months Ended
	Jun. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment, Net	Property, plant and equipment, net are recorded at cost and consisted of the following: As of June 30, December 31, 2024 2023 $ $ Land 65,485 65,485 Building 304,854 231,656 Manufacturing equipment 227,146 186,856 Laboratory equipment 216,673 205,349 Leasehold improvement 60,382 60,124 Software, electronics and office equipment 67,649 83,281 Property, plant and equipment, at cost 942,189 832,751 Less: accumulated depreciation (289,114) (249,212) Construction in progress 863,416 740,615 Property, plant and equipment, net 1,516,491 1,324,154

Intangible Assets (Tables)

Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets Outstanding	Intangible assets as of June 30, 2024 and December 31, 2023 are summarized as follows: As of June 30, 2024 December 31, 2023 Gross Gross carrying Accumulated Intangible carrying Accumulated Intangible amount amortization assets, net amount amortization assets, net $ $ $ $ $ $ Finite-lived intangible assets: Developed products 63,098 (10,054) 53,044 64,274 (7,807) 56,467 Other 8,987 (8,316) 671 8,987 (8,316) 671 Total finite-lived intangible assets 72,085 (18,370) 53,715 73,261 (16,123) 57,138 Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Amortization expense - Cost of sales - product 1,177 840 2,360 1,639 Amortization expense - Operating expense — 188 — 375 Total 1,177 1,028 2,360 2,014
Schedule of Finite-Lived Intangible Assets Amortization Expense	Estimated amortization expense for each of the five succeeding years and thereafter, as of June 30, 2024 is as follows: Year Ending December 31, Cost of Sales - Product Operating Expenses Total $ $ $ 2024 (remainder of year) 2,348 67 2,415 2025 4,696 67 4,763 2026 4,696 67 4,763 2027 4,696 67 4,763 2028 4,696 67 4,763 2029 and thereafter 31,912 336 32,248 Total 53,044 671 53,715

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	6 Months Ended
	Jun. 30, 2024
Balance Sheet Related Disclosures [Abstract]
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following: As of June 30, December 31, 2024 2023 $ $ Prepaid research and development costs 68,234 60,476 Prepaid manufacturing cost 32,986 42,066 Prepaid taxes 32,193 37,320 Other receivables 58,776 37,859 Short-term restricted cash 23,155 11,473 Prepaid insurance 10,158 8,872 Other current assets 48,156 59,399 Total 273,658 257,465
Schedule of Other Non-Current Assets	Other non-current assets consist of the following: As of June 30, December 31, 2024 2023 $ $ Prepayment of property and equipment (1) 34,335 4,144 Prepaid supply cost 12,487 18,122 Prepaid VAT 2,602 2,546 Rental deposits and other 8,002 8,195 Long-term restricted cash 2,121 2,711 Long-term investments (Note 4) 139,771 89,644 Total 199,318 125,362 (1) Includes payment for acquired land use right in Shanghai, China that was in the process of being transitioned to the Company as of June 30, 2024 (See Note 6).
Schedule of Accrued Expenses and Other Payables	Accrued expenses and other payables consist of the following: As of June 30, December 31, 2024 2023 $ $ Compensation related 167,960 217,803 External research and development activities related 133,412 162,969 Commercial activities 70,641 87,572 Individual income tax and other taxes 48,466 30,083 Sales rebates and returns related 173,263 139,936 Other 52,796 55,368 Total 646,538 693,731
Schedule of Other Long-Term Liabilities	Other long-term liabilities consist of the following: As of June 30, December 31, 2024 2023 $ $ Deferred government grant income 32,021 34,204 Pension liability 14,639 14,995 Asset retirement obligation 1,101 1,127 Other 3,772 484 Total 51,533 50,810

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2024
Debt Disclosure [Abstract]
Schedule of Short-Term and Long-Term Debt Obligations	The following table summarizes the Company’s short-term and long-term debt obligations as of June 30, 2024 and December 31, 2023: Lender Line of Credit Term Maturity Date Interest Rate As of June 30, 2024 December 31, 2023 $ RMB $ RMB China Construction Bank RMB580,000 9-year April 4, 2027 (1) 15,136 110,000 14,089 100,000 China Merchants Bank RMB350,000 9-year January 20, 2029 (2) 8,649 62,857 8,856 62,857 China Merchants Bank RMB378,000 9-year November 8, 2029 (3) 6,848 49,765 5,636 40,000 China Merchants Bank $380,000 1-year (4) 380,000 2,761,628 300,000 2,129,321 China Minsheng Bank $150,000 1-year December 19, 2024 7.3% 150,000 1,090,116 150,000 1,064,660 China Industrial Bank RMB 675,000 364-day March 27, 2025 (5) 92,880 675,000 — — China Merchants Bank RMB 400,000 1-year June 5, 2025 3.0% 55,040 400,000 56,356 400,000 HSBC Bank RMB 340,000 1-year May 5, 2025 (6) 46,784 340,000 47,903 340,000 China Industrial Bank RMB 200,000 1-year May 29, 2024 — — — 28,177 200,000 Shanghai Pudong Development Bank RMB 700,000 1-year (7) 2.9% 96,320 700,000 49,312 350,000 Other short-term debt (8) — — 28,037 199,000 Total short-term debt 851,657 6,189,366 688,366 4,885,838 China Construction Bank RMB580,000 9-year April 4, 2027 (1) 49,536 360,000 59,174 420,000 China Merchants Bank RMB350,000 9-year January 20, 2029 (2) 32,434 235,714 37,638 267,143 China Merchants Bank RMB378,000 9-year November 8, 2029 (3) 37,253 270,735 42,337 300,500 China CITIC Bank RMB480,000 10-year July 28, 2032 (9) 66,048 480,000 58,469 415,000 Total long-term bank loans 185,271 1,346,449 197,618 1,402,643 (1) The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 4.2% as of June 30, 2024. The loan is secured by BeiGene Guangzhou Factory’s property ownership certificate. The Company repaid $6,886 (RMB50,000) during the six months ended June 30, 2024. (2) The outstanding borrowings bear floating interest rates benchmarking against prevailing interest rates of certain PRC financial institutions. The loan interest rate was 3.7% as of June 30, 2024. The loan is secured by Guangzhou Factory’s second land use right and certain fixed assets in the second phase of the Guangzhou manufacturing facility’s build out. The Company repaid $4,362 (RMB31,429) during the six months ended June 30, 2024. (3) The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 3.9% as of June 30, 2024. The loan is secured by fixed assets placed into service upon completion of the third phase of the Guangzhou manufacturing facility’s build out. The Company repaid $2,772 (RMB20,000) during the six months ended June 30, 2024. (4) The outstanding borrowings bear floating interest rates benchmarking the secured overnight financing rate. The loan interest rate was 7.2% as of June 30, 2024. $300,000 of the borrowings matures on December 25, 2024, and $80,000 matures on January 27, 2025. (5) The outstanding borrowings bear floating interest rates benchmarking RMB loan interest rates of financial institutions in the PRC. The loan interest rate was 2.6% as of June 30, 2024. (6) The outstanding borrowings bear floating interest rates benchmarking Hong Kong interbank market rate for RMB. The loan interest rate was 5.7% as of June 30, 2024. (7) $48,160 (RMB350,000) of the outstanding borrowings matures on November 21, 2024 and March 19, 2025, respectively. (8) During the two years ended December 31, 2023, the Company entered into short-term working capital loans with China Industrial Bank and China Merchants Bank to borrow up to RMB875,000 in aggregate. The Company repaid $27,476 (RMB199,000) during the six months ended June 30, 2024. (9) In July 2022, the Company entered into a 10-year bank loan agreement with China CITIC Bank to borrow up to RMB480,000 at a floating interest rate benchmarked against prevailing interest rates of certain PRC financial institutions. The Company drew down $9,053 (RMB65,000) during the six months ended June 30, 2024. The weighted average loan interest rate was 3.9% as of June 30, 2024. The loan is secured by BeiGene Suzhou Co., Ltd.’s property ownership certificate of the small molecule manufacturing campus in Suzhou, China.

Product Revenue (Tables)

Product Revenue (Tables)	6 Months Ended
	Jun. 30, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Net Product Sales	The following table summarizes total collaboration revenue recognized for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 Revenue from Collaborators $ $ $ $ Research and development service revenue — 13,563 — 20,380 Right to access intellectual property revenue — 26,248 — 52,497 Other 8,020 1,705 12,754 6,149 Total 8,020 41,516 12,754 79,026 Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 11,770 — 16,796 Other (1) 2,113 1,344 2,113 5,013 Total 2,113 13,114 2,113 21,809 (1) Represents revenue recognized on final shipment of tislelizumab clinical supply to Novartis in conjunction with the former collaboration. The following table summarizes collaboration revenue recognized in connection with the China broad markets agreement for the three and six months ended June 30, 2024 and the terminated ociperlimab option, collaboration and license agreement for the three and six months ended June 30, 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development service revenue — 1,792 — 3,583 Right to access intellectual property revenue — 26,248 — 52,497 China broad markets agreement 4,154 1,861 8,501 2,636 Total 4,154 29,901 8,501 58,716 The table below presents the Company’s net product sales for the three and six months ended June 30, 2024 and 2023. Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Product revenue – gross 1,167,155 667,328 2,111,619 1,176,933 Less: Rebates and sales returns (246,009) (113,583) (443,555) (212,897) Product revenue – net 921,146 553,745 1,668,064 964,036 The following table disaggregates net product sales by product for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ BRUKINSA ® 637,399 308,276 1,125,914 519,658 Tislelizumab 158,410 149,464 303,687 264,314 XGEVA ® 55,054 23,968 98,435 44,165 BLINCYTO ® 19,131 14,578 33,497 25,524 KYPROLIS ® 15,936 11,052 30,047 15,995 POBEVCY ® 11,572 13,438 28,205 27,764 REVLIMID ® 9,133 21,847 21,366 45,005 Other 14,511 11,122 26,913 21,611 Total product revenue – net 921,146 553,745 1,668,064 964,036
Schedule of Accrued Sales Rebates and Returns	The following table presents the roll-forward of accrued sales rebates and returns for the six months ended June 30, 2024 and 2023: Six Months Ended June 30, 2024 2023 $ $ Balance at beginning of the period 139,936 41,817 Accrual 443,555 212,897 Payments (410,228) (169,123) Balance at end of the period 173,263 85,591

Loss Per Share (Tables)

Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of the Computations of Basic and Diluted Loss Per Share	The following table reconciles the numerator and denominator in the computations of basic and diluted loss per share: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Numerator: Net loss (120,405) (381,137) (371,555) (729,568) Denominator: Weighted average shares outstanding for computing basic and diluted loss per share 1,361,082,567 1,360,224,377 1,358,315,145 1,357,211,308 Loss per share (0.09) (0.28) (0.27) (0.54)

Share-Based Compensation Expe_2

Share-Based Compensation Expense (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Shares Issued Under Employee Share Purchase Plan	The following tables summarizes the shares issued under the ESPP: Market Price 1 Purchase Price 2 Issuance Date Number of Ordinary Shares Issued ADS Ordinary ADS Ordinary Proceeds February 29, 2024 1,021,397 $ 165.65 $ 12.74 $ 140.80 $ 10.83 $ 11,063 August 31, 2023 794,144 $ 207.55 $ 15.97 $ 176.42 $ 13.57 $ 10,777 February 28, 2023 930,582 $ 171.10 $ 13.16 $ 145.44 $ 11.19 $ 10,414 1 The market price is the lower of the closing price on the Nasdaq Stock Market on the issuance date or the offering date, in accordance with the terms of the ESPP. 2 The purchase price is the price which was discounted from the applicable market price, in accordance with the terms of the ESPP.
Schedule of Total Compensation Cost Recognized	The following table summarizes total share-based compensation expense recognized for the three and six months ended June 30, 2024 and 2023: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ Research and development 55,406 45,948 93,451 79,976 Selling, general and administrative 75,288 57,381 125,957 98,741 Total 130,694 103,329 219,408 178,717

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Loss	The movement of accumulated other comprehensive loss was as follows: Unrealized Foreign Currency Gains/(Losses) on Pension Translation Available-for-Sale Liability Adjustments Securities Adjustments Total $ $ $ $ Balance as of December 31, 2023 (87,987) 35 (11,494) (99,446) Other comprehensive (loss) income before reclassifications (41,399) (35) — (41,434) Amounts reclassified from accumulated other comprehensive income (loss) — — 406 406 Net-current period other comprehensive (loss) income (41,399) (35) 406 (41,028) Balance as of June 30, 2024 (129,386) — (11,088) (140,474)

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of Net Product Revenues by Geographic Area	Total revenues by geographic area are presented as follows: Three Months Ended Six Months Ended June 30, June 30, 2024 2023 2024 2023 $ $ $ $ U.S. - total revenue 481,430 252,347 832,886 416,830 Product revenue 479,365 223,539 830,821 362,307 Collaboration revenue 2,065 28,808 2,065 54,523 China- total revenue 352,070 295,783 672,446 543,464 Product revenue 347,112 293,922 662,774 540,828 Collaboration revenue 4,958 1,861 9,672 2,636 Europe- total revenue 82,389 37,169 149,249 67,690 Product revenue 81,392 26,322 148,232 45,823 Collaboration revenue 997 10,847 1,017 21,867 Rest of world- total revenue 13,277 9,962 26,237 15,078 Product revenue 13,277 9,962 26,237 15,078 Collaboration revenue — — — — Total Revenue 929,166 595,261 1,680,818 1,043,062

Description of Business, Basi_3

Description of Business, Basis of Presentation and Consolidation and Significant Accounting Policies (Details) person in Thousands	Jun. 30, 2024 person medicine
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of approved medicines | medicine	3
Number of internal clinical teams | person	3

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring Basis - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Quoted Price in Active Market for Identical Assets (Level 1)
Other non-current assets (Note 4):
Total	$ 899,346	$ 1,100,647
Quoted Price in Active Market for Identical Assets (Level 1) | U.S. Treasury securities
Prepaid expenses and other current assets:
U.S. Treasury securities		2,600
Quoted Price in Active Market for Identical Assets (Level 1) | Convertible debt instrument
Prepaid expenses and other current assets:
Convertible debt instrument	0	0
Other non-current assets (Note 4):
Convertible debt instrument	0	0
Quoted Price in Active Market for Identical Assets (Level 1) | Equity securities with readily determinable fair values
Other non-current assets (Note 4):
Equity securities with readily determinable fair values	1,440	3,046
Quoted Price in Active Market for Identical Assets (Level 1) | Money market funds
Assets at fair value on a recurring basis
Cash equivalents	897,906	1,052,149
Quoted Price in Active Market for Identical Assets (Level 1) | Time deposits
Assets at fair value on a recurring basis
Cash equivalents		42,852
Significant Other Observable Inputs (Level 2)
Other non-current assets (Note 4):
Total	115	542
Significant Other Observable Inputs (Level 2) | U.S. Treasury securities
Prepaid expenses and other current assets:
U.S. Treasury securities		0
Significant Other Observable Inputs (Level 2) | Convertible debt instrument
Prepaid expenses and other current assets:
Convertible debt instrument	0	0
Other non-current assets (Note 4):
Convertible debt instrument	0	0
Significant Other Observable Inputs (Level 2) | Equity securities with readily determinable fair values
Other non-current assets (Note 4):
Equity securities with readily determinable fair values	115	542
Significant Other Observable Inputs (Level 2) | Money market funds
Assets at fair value on a recurring basis
Cash equivalents	0	0
Significant Other Observable Inputs (Level 2) | Time deposits
Assets at fair value on a recurring basis
Cash equivalents		0
Significant Unobservable Inputs (Level 3)
Other non-current assets (Note 4):
Total	9,741	8,883
Significant Unobservable Inputs (Level 3) | U.S. Treasury securities
Prepaid expenses and other current assets:
U.S. Treasury securities		0
Significant Unobservable Inputs (Level 3) | Convertible debt instrument
Prepaid expenses and other current assets:
Convertible debt instrument	4,968	4,668
Other non-current assets (Note 4):
Convertible debt instrument	4,773	4,215
Significant Unobservable Inputs (Level 3) | Equity securities with readily determinable fair values
Other non-current assets (Note 4):
Equity securities with readily determinable fair values	0	0
Significant Unobservable Inputs (Level 3) | Money market funds
Assets at fair value on a recurring basis
Cash equivalents	$ 0	0
Significant Unobservable Inputs (Level 3) | Time deposits
Assets at fair value on a recurring basis
Cash equivalents		$ 0

Collaborative and Licensing A_3

Collaborative and Licensing Arrangements - Recognized Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Total revenues	$ 929,166	$ 595,261	$ 1,680,818	$ 1,043,062
Collaboration
Revenues
Total revenues	8,020	41,516	12,754	79,026
Collaboration | Novartis
Revenues
Total revenues	8,020	41,516	12,754	79,026
Collaboration | Tislelizumab
Revenues
Total revenues	2,113	13,114	2,113	21,809
Collaboration | Ociperlimab
Revenues
Total revenues	4,154	29,901	8,501	58,716
Research and development service revenue | Novartis
Revenues
Total revenues	0	13,563	0	20,380
Research and development service revenue | Tislelizumab
Revenues
Total revenues	0	11,770	0	16,796
Research and development service revenue | Ociperlimab
Revenues
Total revenues	0	1,792	0	3,583
Right to access intellectual property revenue | Novartis
Revenues
Total revenues	0	26,248	0	52,497
Right to access intellectual property revenue | Ociperlimab
Revenues
Total revenues	0	26,248	0	52,497
Other | Novartis
Revenues
Total revenues	8,020	1,705	12,754	6,149
Other | Tislelizumab
Revenues
Total revenues	2,113	1,344	2,113	5,013
China broad markets agreement | Ociperlimab
Revenues
Total revenues	$ 4,154	$ 1,861	$ 8,501	$ 2,636

Collaborative and Licensing A_4

Collaborative and Licensing Arrangements - Funding Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Research and Development Arrangement, Contract to Perform for Others
Research and development expense	$ 454,466	$ 422,764	$ 915,104	$ 831,348
Amgen, Inc
Research and Development Arrangement, Contract to Perform for Others
Research and development expense	22,482	5,457	35,966	23,274
Amortization of research and development cost share liability	21,903	5,271	35,039	22,669
Total amount due to Amgen for BeiGene’s portion of the development funding	44,385	$ 10,728	71,005	$ 45,943
Remaining portion of development funding cap	$ 412,647		$ 412,647

Collaborative and Licensing A_5

Collaborative and Licensing Arrangements - Financing Liability (Details) - Amgen, Inc - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Research and Development Arrangement, Contract to Perform for Others
Research and development cost share liability, current portion	$ 84,615	$ 68,004
Research and development cost share liability, non-current portion	119,012	170,662
Total research and development cost share liability	$ 203,627	$ 238,666

Collaborative and Licensing A_6

Collaborative and Licensing Arrangements - Amounts and Classification of Payments (Income/(Expense) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Research and Development Arrangement, Contract to Perform for Others
Total	$ (11,949)	$ (15,310)	$ (22,238)	$ (26,893)
Accounts payable	333,022		333,022		$ 315,111
Amgen, Inc | Collaborative Arrangement
Research and Development Arrangement, Contract to Perform for Others
Collaborative arrangement, inventory purchases	47,653	20,146	109,879	39,277
Amgen, Inc | Collaborative Arrangement | Related Party
Research and Development Arrangement, Contract to Perform for Others
Accounts payable	66,824		66,824		$ 55,474
Cost of sales - product
Research and Development Arrangement, Contract to Perform for Others
Total	9,590	4,011	18,159	1,184
Research and development
Research and Development Arrangement, Contract to Perform for Others
Total	(439)	(1,769)	(1,144)	1,311
Selling, general and administrative
Research and Development Arrangement, Contract to Perform for Others
Total	$ (21,100)	$ (17,552)	$ (39,253)	$ (29,388)

Collaborative Arrangements - In

Collaborative Arrangements - In Licensing Agreements-Development (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Collaborative Arrangement and Arrangement Other than Collaborative
Total	$ 11,500	$ 0	$ 46,527	$ 0
Upfront payments | Research and development expense
Collaborative Arrangement and Arrangement Other than Collaborative
Total	0	0	27	0
Development milestones incurred | Research and development expense
Collaborative Arrangement and Arrangement Other than Collaborative
Total	$ 11,500	$ 0	$ 46,500	$ 0

Restricted Cash and Investmen_3

Restricted Cash and Investments - Schedule of Restrictions on Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Short-term restricted cash	$ 23,155	$ 11,473
Long-term restricted cash	2,121	2,711
Total	$ 25,276	$ 14,184

Restricted Cash and Investmen_4

Restricted Cash and Investments - Narrative (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Schedule of Investments
Restricted cash	$ 25,276	$ 14,184
STAR Market | IPO
Schedule of Investments
Restricted cash	$ 856,722

Restricted Cash and Investmen_5

Restricted Cash and Investments - Investments In Equity Securities (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Dec. 31, 2023
Schedule of Investments
Equity-method investments	$ 37,780		$ 37,780	$ 25,981
Total	134,998		134,998	85,429
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Pi Health, Inc
Schedule of Investments
Divested net assets carrying value		$ 38,063
Proceeds from divestiture of businesses	1
Pre-tax gain			3,735
Leap Therapeutic, Inc | Ordinary Shares
Schedule of Investments
Equity securities with readily determinable fair values	1,440		1,440	3,046
Leap Therapeutic, Inc | Warrant
Schedule of Investments
Equity securities with readily determinable fair values	115		115	542
Pi Health, Inc
Schedule of Investments
Equity securities without readily determinable fair values	40,798		40,798	0
Other
Schedule of Investments
Equity securities without readily determinable fair values	$ 54,865		$ 54,865	$ 55,860

Restricted Cash and Investmen_6

Restricted Cash and Investments - Equity Method Investments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Equity securities with readily determinable fair values	$ (621)	$ 470	$ (2,033)	$ (636)
Equity securities without readily determinable fair values	0	0		1,081
Equity securities without readily determinable fair values			(797)
Equity-method investments	$ (4,017)	$ (2,480)	$ (4,873)	$ (2,624)

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials	$ 143,655	$ 148,772
Work in process	59,499	39,098
Finished goods	240,106	228,252
Total inventories, net	$ 443,260	$ 416,122

Property, Plant and Equipment_3

Property, Plant and Equipment, Net- Schedule of Property, Plant and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property and equipment
Property, plant and equipment, at cost	$ 942,189	$ 832,751
Less: accumulated depreciation	(289,114)	(249,212)
Construction in progress	863,416	740,615
Property, plant and equipment, net	1,516,491	1,324,154
Land
Property and equipment
Property, plant and equipment, at cost	65,485	65,485
Building
Property and equipment
Property, plant and equipment, at cost	304,854	231,656
Manufacturing equipment
Property and equipment
Property, plant and equipment, at cost	227,146	186,856
Laboratory equipment
Property and equipment
Property, plant and equipment, at cost	216,673	205,349
Leasehold improvement
Property and equipment
Property, plant and equipment, at cost	60,382	60,124
Software, electronics and office equipment
Property and equipment
Property, plant and equipment, at cost	$ 67,649	$ 83,281

Property, Plant and Equipment_4

Property, Plant and Equipment, Net - Narratives (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		6 Months Ended
	May 31, 2024	Mar. 31, 2024	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Dec. 31, 2023
Property, Plant and Equipment
Construction in progress			$ 863,416		$ 863,416		$ 740,615
Purchases of property, plant and equipment					266,528	$ 247,055
Depreciation expense			23,754	$ 21,307	47,864	$ 40,332
Shanghai, China
Property, Plant and Equipment
Purchases of property, plant and equipment		$ 73,373
Land | Shanghai, China
Property, Plant and Equipment
Purchases of property, plant and equipment		28,699
Construction in progress
Property, Plant and Equipment
Purchases of property, plant and equipment	$ 22,637
Construction in progress | Shanghai, China
Property, Plant and Equipment
Purchases of property, plant and equipment		$ 44,674
Land Located in Hopewell, NJ | Land
Property, Plant and Equipment
Construction in progress			$ 677,126		$ 677,126

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets Outstanding (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Finite-lived intangible assets:
Gross carrying amount	$ 72,085	$ 73,261
Accumulated amortization	(18,370)	(16,123)
Total	53,715	57,138
Developed products
Finite-lived intangible assets:
Gross carrying amount	63,098	64,274
Accumulated amortization	(10,054)	(7,807)
Total	53,044	56,467
Other
Finite-lived intangible assets:
Gross carrying amount	8,987	8,987
Accumulated amortization	(8,316)	(8,316)
Total	$ 671	$ 671

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details) - Weighted Average	Jun. 30, 2024
Developed products
Acquired Finite-Lived Intangible Assets
Useful life	12 years
Other
Acquired Finite-Lived Intangible Assets
Useful life	12 years

Intangible Assets - Future Amor

Intangible Assets - Future Amortization Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Finite-Lived Intangible Assets
Amortization of intangible assets	$ 1,177	$ 1,028	$ 2,360	$ 2,014
Cost of sales - product
Finite-Lived Intangible Assets
Amortization of intangible assets	1,177	840	2,360	1,639
Operating Expenses
Finite-Lived Intangible Assets
Amortization of intangible assets	$ 0	$ 188	$ 0	$ 375

Intangible Assets - Expected Am

Intangible Assets - Expected Amortization Expense (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Acquired Finite-Lived Intangible Assets
2024 (remainder of year)	$ 2,415
2025	4,763
2026	4,763
2027	4,763
2028	4,763
2029 and thereafter	32,248
Total	53,715	$ 57,138
Cost of Sales - Product
Acquired Finite-Lived Intangible Assets
2024 (remainder of year)	2,348
2025	4,696
2026	4,696
2027	4,696
2028	4,696
2029 and thereafter	31,912
Total	53,044
Operating Expenses
Acquired Finite-Lived Intangible Assets
2024 (remainder of year)	67
2025	67
2026	67
2027	67
2028	67
2029 and thereafter	336
Total	$ 671

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income taxes
Income tax expense	$ 14,485	$ 13,674	$ 22,209	$ 25,166
Unrecognized tax benefits	15,804		15,804
Increase in uncertain tax position	$ 880		$ 1,540

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023	Jun. 30, 2023
Prepaid expenses and other current assets
Prepaid research and development costs	$ 68,234	$ 60,476
Prepaid manufacturing cost	32,986	42,066
Prepaid taxes	32,193	37,320
Other receivables	58,776	37,859
Short-term restricted cash	23,155	11,473	$ 9,693
Prepaid insurance	10,158	8,872
Other current assets	48,156	59,399
Total	$ 273,658	$ 257,465

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Schedule of Other Non-current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Other non-current assets
Prepayment of property and equipment	$ 34,335	$ 4,144
Prepaid supply cost	12,487	18,122
Prepaid VAT	2,602	2,546
Rental deposits and other	8,002	8,195
Long-term restricted cash	2,121	2,711
Long-term investments (Note 4)	139,771	89,644
Total	$ 199,318	$ 125,362

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Schedule of Accrued Expenses and Other Payables (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Accrued expenses and other payables
Compensation related	$ 167,960	$ 217,803
External research and development activities related	133,412	162,969
Commercial activities	70,641	87,572
Individual income tax and other taxes	48,466	30,083
Sales rebates and returns related	173,263	139,936
Other	52,796	55,368
Total	$ 646,538	$ 693,731

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Schedule of Other Long-term Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Other long-term liabilities
Deferred government grant income	$ 32,021	$ 34,204
Pension liability	14,639	14,995
Asset retirement obligation	1,101	1,127
Other	3,772	484
Total	$ 51,533	$ 50,810

Debt - Short-term and Long-term

Debt - Short-term and Long-term Debt Obligations (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CNY (¥)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CNY (¥)
Debt Instrument
Short-term debt	$ 851,657,000	¥ 6,189,366,000	$ 688,366,000	¥ 4,885,838,000
Long-term debt	$ 185,271,000	1,346,449,000	197,618,000	1,402,643,000
Loans Payable
Debt Instrument
Line of Credit				875,000,000
China Industrial Bank | Loans Payable
Debt Instrument
Interest Rate	2.60%
Short Term Bank Loan Dated April 4 2018 | China Construction Bank | Loans Payable
Debt Instrument
Line of Credit		580,000
Term	9 years
Short-term debt	$ 15,136,000	110,000,000	14,089,000	100,000,000
Short Term Bank Loan Dated January 22, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit		350,000
Term	9 years
Interest Rate	3.70%
Short-term debt	$ 8,649,000	62,857,000	8,856,000	62,857,000
Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Interest Rate	3.90%
Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit		378,000,000
Term	9 years
Short-term debt	$ 6,848,000	49,765,000	5,636,000	40,000,000
Short Term Bank Loan Dated July 28, 2023 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit | $	$ 380,000,000
Term	1 year
Short-term debt	$ 380,000,000	2,761,628,000	300,000,000	2,129,321,000
Short Term Bank Loan Dated July 28, 2023 | China Minsheng Bank | Loans Payable
Debt Instrument
Interest Rate	7.20%
Short Term Bank Loan Dated December 20, 2023 | China Minsheng Bank | Loans Payable
Debt Instrument
Line of Credit | $	$ 150,000,000
Term	1 year
Interest Rate	7.30%
Short-term debt	$ 150,000,000	1,090,116,000	150,000,000	1,064,660,000
Short Term Bank Loan Dated March 21, 2024 | China Industrial Bank | Loans Payable
Debt Instrument
Line of Credit		675,000
Term	364 days
Short-term debt	$ 92,880,000	675,000,000	0	0
Short Term Bank Loan Dated June 5 2023 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit		400,000
Term	1 year
Interest Rate	3%
Short-term debt	$ 55,040,000	400,000,000	56,356,000	400,000,000
Short Term Bank Loan Dated May 4 2023 | HSBC Bank | Loans Payable
Debt Instrument
Line of Credit		340,000
Term	1 year
Interest Rate	5.70%
Short-term debt	$ 46,784,000	340,000,000	47,903,000	340,000,000
Short Term Bank Loan Dated May 30 2023 | China Industrial Bank | Loans Payable
Debt Instrument
Line of Credit		200,000
Term	1 year
Interest Rate	0%
Short-term debt	$ 0	0	28,177,000	200,000,000
Short Term Bank Loan Dated November 14, 2023 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Line of Credit		700,000
Term	1 year
Interest Rate	2.90%
Short-term debt	$ 96,320,000	700,000,000	49,312,000	350,000,000
Long Term Bank Loan Dated April 4, 2018 | China Construction Bank | Loans Payable
Debt Instrument
Line of Credit		580,000
Term	9 years
Interest Rate	4.20%
Long-term debt	$ 49,536,000	360,000,000	59,174,000	420,000,000
Long Term Bank Loan Dated January 22, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit		350,000
Term	9 years
Long-term debt	$ 32,434,000	235,714,000	37,638,000	267,143,000
Long Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Line of Credit		378,000
Term	9 years
Long-term debt	$ 37,253,000	270,735,000	42,337,000	300,500,000
Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank
Debt Instrument
Line of Credit		480,000,000
Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank | Loans Payable
Debt Instrument
Line of Credit		480,000
Term	10 years
Long-term debt	$ 66,048,000	480,000,000	58,469,000	415,000,000
Short Term Bank Loan Dated November 21, 2024 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Short-term debt	48,160,000	350,000,000
Short Term Bank Loan Dated March 19, 2025 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Short-term debt	48,160,000	350,000,000
Other Short Term Debt | Loans Payable
Debt Instrument
Short-term debt	$ 0	¥ 0	$ 28,037,000	¥ 199,000,000

Debt - Footnotes (Details)

Debt - Footnotes (Details)	6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2024 CNY (¥)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 CNY (¥)	Dec. 31, 2023 USD ($)	Dec. 31, 2023 CNY (¥)
Debt Instrument
Repayment of short-term loans | $	$ 157,490,000		$ 66,574,000
Repayments of long-term debt | $	14,020,000		0
Proceeds from long-term loan | $	9,053,000		$ 15,771,000
Short-term debt	$ 851,657,000			¥ 6,189,366,000	$ 688,366,000	¥ 4,885,838,000
Loans Payable
Debt Instrument
Line of credit						875,000,000
China Industrial Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period	2.60%	2.60%
Long Term Bank Loan Dated April 4, 2018 | China Construction Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period	4.20%	4.20%
Repayment of short-term loans	$ 6,886,000	¥ 50,000,000
Line of credit				580,000
Debt instrument term (in years)	9 years	9 years
Short Term Bank Loan Dated January 22, 2020 | China Construction Bank | Loans Payable
Debt Instrument
Repayment of short-term loans	$ 4,362,000	¥ 31,429,000
Short Term Bank Loan Dated January 22, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period	3.70%	3.70%
Line of credit				350,000
Debt instrument term (in years)	9 years	9 years
Short-term debt	$ 8,649,000			62,857,000	8,856,000	62,857,000
Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Repayments of long-term debt	$ 2,772,000	¥ 20,000,000
Line of credit				378,000,000
Debt instrument term (in years)	9 years	9 years
Short-term debt	$ 6,848,000			49,765,000	5,636,000	40,000,000
Short Term Bank Loan Dated November 9, 2020 | China Merchants Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period	3.90%	3.90%
Short Term Bank Loan Dated July 28, 2023 | China Merchants Bank | Loans Payable
Debt Instrument
Line of credit | $	$ 380,000,000
Debt instrument term (in years)	1 year	1 year
Short-term debt	$ 380,000,000			2,761,628,000	300,000,000	2,129,321,000
Short Term Bank Loan Dated July 28, 2023 | China Minsheng Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period	7.20%	7.20%
Short Term Bank Loan Dated May 4 2023 | HSBC Bank | Loans Payable
Debt Instrument
Debt instrument, interest rate during period	5.70%	5.70%
Line of credit				340,000
Debt instrument term (in years)	1 year	1 year
Short-term debt	$ 46,784,000			340,000,000	47,903,000	340,000,000
Short Term Bank Loan Dated November 21, 2024 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Short-term debt	48,160,000			350,000,000
Short Term Bank Loan Dated March 19, 2025 | Shanghai Pudong Development Bank | Loans Payable
Debt Instrument
Short-term debt	$ 48,160,000			¥ 350,000,000
Long Term Bank Loan Dated July 29, 2022 | China Merchants Bank | Loans Payable
Debt Instrument
Fixed annual interest rate (as a percent)	3.90%			3.90%
Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank
Debt Instrument
Line of credit				¥ 480,000,000
Long Term Bank Loan Dated July 29, 2022 | China CITIC Bank | Loans Payable
Debt Instrument
Line of credit				480,000
Debt instrument term (in years)	10 years	10 years
Proceeds from long-term loan	$ 9,053,000	¥ 65,000,000
Other Short Term Debt | Loans Payable
Debt Instrument
Repayment of short-term loans	27,476,000	¥ 199,000,000
Short-term debt	0			¥ 0	$ 28,037,000	¥ 199,000,000
Short Term Bank Loan Maturing December252024 | China Minsheng Bank | Loans Payable
Debt Instrument
Short-term debt | $	300,000,000
Short Term Bank Loan Maturing January 27, 2025 | China Minsheng Bank | Loans Payable
Debt Instrument
Short-term debt | $	$ 80,000,000

Debt - Narratives (Details)

Debt - Narratives (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Debt Disclosure [Abstract]
Interest expense	$ 13,233	$ 4,891	$ 25,637	$ 9,465
Interest capitalized	$ 8,312	$ 428	$ 17,521	$ 772

Product Revenue - Schedule of N

Product Revenue - Schedule of Net Product Sales (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues
Product revenue – net	$ 929,166	$ 595,261	$ 1,680,818	$ 1,043,062
Product revenue
Revenues
Product revenue – gross	1,167,155	667,328	2,111,619	1,176,933
Less: Rebates and sales returns	(246,009)	(113,583)	(443,555)	(212,897)
Product revenue – net	921,146	553,745	1,668,064	964,036
Product revenue | BRUKINSA®
Revenues
Product revenue – net	637,399	308,276	1,125,914	519,658
Product revenue | Tislelizumab
Revenues
Product revenue – net	158,410	149,464	303,687	264,314
Product revenue | XGEVA®
Revenues
Product revenue – net	55,054	23,968	98,435	44,165
Product revenue | BLINCYTO®
Revenues
Product revenue – net	19,131	14,578	33,497	25,524
Product revenue | KYPROLIS®
Revenues
Product revenue – net	15,936	11,052	30,047	15,995
Product revenue | POBEVCY®
Revenues
Product revenue – net	11,572	13,438	28,205	27,764
Product revenue | REVLIMID®
Revenues
Product revenue – net	9,133	21,847	21,366	45,005
Product revenue | Other
Revenues
Product revenue – net	$ 14,511	$ 11,122	$ 26,913	$ 21,611

Product Revenue - Schedule of A

Product Revenue - Schedule of Accrued Sales Rebates and Returns (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Accrued Sales Rebates and Returns
Balance at beginning of the period	$ 139,936
Balance at end of the period	173,263
Product revenue
Accrued Sales Rebates and Returns
Balance at beginning of the period	139,936	$ 41,817
Accrual	443,555	212,897
Payments	(410,228)	(169,123)
Balance at end of the period	$ 173,263	$ 85,591

Loss Per Share - Schedule of th

Loss Per Share - Schedule of the Computations of Basic and Diluted Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Numerator:
Net loss	$ (120,405)	$ (251,150)	$ (381,137)	$ (348,431)	$ (371,555)	$ (729,568)
Denominator:
Weighted average shares outstanding for computing basic loss per share (in shares)	1,361,082,567		1,360,224,377		1,358,315,145	1,357,211,308
Weighted average shares outstanding for computing diluted loss per share (in shares)	1,361,082,567		1,360,224,377		1,358,315,145	1,357,211,308
Loss per share basic (in dollars per share)	$ (0.09)		$ (0.28)		$ (0.27)	$ (0.54)
Loss per share diluted (in dollars per share)	$ (0.09)		$ (0.28)		$ (0.27)	$ (0.54)

Share-Based Compensation Expe_3

Share-Based Compensation Expense - Narrative (Details) - shares		1 Months Ended			6 Months Ended
	Jun. 22, 2022	Jun. 30, 2024	Jun. 30, 2020	Dec. 31, 2018	Jun. 30, 2024	Jun. 30, 2018	Jan. 31, 2016
2016 Share Option and Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares reserved and available for issuance (in shares)							65,029,595
Increase in ordinary shares authorized (in shares)	66,300,000		57,200,000	38,553,159
2016 Share Option and Incentive Plan | Share Options
Share-based Compensation Arrangement by Share-based Payment Award
Granted (in shares)					8,394,737
Number of options outstanding (in shares)		67,378,462			67,378,462
2016 Share Option and Incentive Plan | Restricted Share Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award
Granted (in shares)					42,514,355
Number of options outstanding (in shares)		87,422,244			87,422,244
2016 Share Option and Incentive Plan | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award
Granted (in shares)					2,287,402
Number of options outstanding (in shares)		2,287,402			2,287,402
2016 Share Option and Incentive Plan | Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award
Shares available for future grants (in shares)		82,059,496			82,059,496
Third Amended and Restated 2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award
Increase in ordinary shares authorized (in shares)		92,820,000
2011 Plan
Share-based Compensation Arrangement by Share-based Payment Award
Shares cancelled or forfeited (in shares)					5,166,848
Employee Share Purchase Plan 2018
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares reserved and available for issuance (in shares)				7,355,315		3,500,000
Increase in ordinary shares authorized (in shares)		5,070,000		3,855,315
Shares available for future grants (in shares)		5,989,678			5,989,678
Offering period					6 months
Discount on purchase price of common stock (as a percent)						15%
Maximum percentage of eligible earnings as after-tax withholdings to purchase ordinary shares (as a percent)					10%

Share-Based Compensation Expe_4

Share-Based Compensation Expense - Schedule of Shares Issued Under Employee Share Purchase Plan (Details) - Employee Share Purchase Plan 2018 - USD ($) $ / shares in Units, $ in Thousands	Feb. 29, 2024	Aug. 31, 2023	Feb. 28, 2023
Share-based Compensation Arrangement by Share-based Payment Award
Number of Ordinary Shares Issued ( in shares)	1,021,397	794,144	930,582
Market Price, ADS (in dollars per share)	$ 165.65	$ 207.55	$ 171.10
Market Price, Ordinary (in dollars per share)	12.74	15.97	13.16
Purchase Price, ADS (in dollars per share)	140.80	176.42	145.44
Purchase Price, Ordinary (in dollars per share)	$ 10.83	$ 13.57	$ 11.19
Proceeds	$ 11,063	$ 10,777	$ 10,414

Share-Based Compensation Expe_5

Share-Based Compensation Expense - Schedule of Total Compensation Cost Recognized (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Share-based compensation
Compensation expense	$ 130,694	$ 103,329	$ 219,408	$ 178,717
Research and development
Share-based compensation
Compensation expense	55,406	45,948	93,451	79,976
Selling, general and administrative
Share-based compensation
Compensation expense	$ 75,288	$ 57,381	$ 125,957	$ 98,741

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024
Movement in accumulated other comprehensive loss
Balance at the beginning of period		$ 3,537,327			$ 3,537,327
Other comprehensive (loss) income before reclassifications					(41,434)
Amounts reclassified from accumulated other comprehensive income (loss)					406
Net-current period other comprehensive (loss) income	$ (8,830)	(32,198)	$ (84,673)	$ 18,403	(41,028)
Balance at the beginning of period	3,366,255				3,366,255
Accumulated Other Comprehensive Loss
Movement in accumulated other comprehensive loss
Balance at the beginning of period		(99,446)			(99,446)
Net-current period other comprehensive (loss) income	(8,830)	(32,198)	$ (84,673)	$ 18,403
Balance at the beginning of period	(140,474)				(140,474)
Foreign Currency Translation Adjustments
Movement in accumulated other comprehensive loss
Balance at the beginning of period		(87,987)			(87,987)
Other comprehensive (loss) income before reclassifications					(41,399)
Amounts reclassified from accumulated other comprehensive income (loss)					0
Net-current period other comprehensive (loss) income					(41,399)
Balance at the beginning of period	(129,386)				(129,386)
Unrealized Gains (Losses) on Available-for-Sale Securities
Movement in accumulated other comprehensive loss
Balance at the beginning of period		35			35
Other comprehensive (loss) income before reclassifications					(35)
Amounts reclassified from accumulated other comprehensive income (loss)					0
Net-current period other comprehensive (loss) income					(35)
Balance at the beginning of period	0				0
Pension Liability Adjustments
Movement in accumulated other comprehensive loss
Balance at the beginning of period		$ (11,494)			(11,494)
Other comprehensive (loss) income before reclassifications					0
Amounts reclassified from accumulated other comprehensive income (loss)					406
Net-current period other comprehensive (loss) income					406
Balance at the beginning of period	$ (11,088)				$ (11,088)

Shareholders_ Equity (Details)

Shareholders’ Equity (Details) - USD ($) $ in Thousands	Aug. 15, 2023	Aug. 01, 2023
Ordinary Shares
Subsidiary, Sale of Stock
Cancellation of ordinary shares (in share)		23,273,108
Total
Subsidiary, Sale of Stock
Cancellation of ordinary shares	$ 362,917

Restricted Net Assets (Details)

Restricted Net Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Segment Reporting Information
Minimum required statutory reserve of annual after-tax profit (as a percent)	10%
Required statutory reserve as a percentage of registered capital (as a percent)	50%
China
Segment Reporting Information
Restricted net assets	$ 1,378,872	$ 1,837,790

Commitments and Contingencies -

Commitments and Contingencies - Commitments (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($) investment
Purchase and Capital commitments
Purchase commitments	$ 120,366
Investments Funding Commitment
Purchase and Capital commitments
Other commitments	$ 8,154
Number of equity investments | investment	2
Maximum commitment	$ 15,054
Amgen, Inc
Purchase and Capital commitments
Other commitments	412,647
Maximum cash and development services commitment	1,250,000
Minimum Purchase Commitments For Supply Purchased
Purchase and Capital commitments
Purchase commitments	28,822
Inventories
Purchase and Capital commitments
Purchase commitments	91,544
Capital Addition Purchase Commitments
Purchase and Capital commitments
Other commitments	$ 62,576

Segment and Geographic Inform_3

Segment and Geographic Information - Narratives (Details)	6 Months Ended
	Jun. 30, 2024 segment
Segment Reporting [Abstract]
Number of operating segments	1

Segment and Geographic Inform_4

Segment and Geographic Information - Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Net product revenues by geographic area
Total Revenue	$ 929,166	$ 595,261	$ 1,680,818	$ 1,043,062
U.S. - total revenue
Net product revenues by geographic area
Total Revenue	481,430	252,347	832,886	416,830
China- total revenue
Net product revenues by geographic area
Total Revenue	352,070	295,783	672,446	543,464
Europe- total revenue
Net product revenues by geographic area
Total Revenue	82,389	37,169	149,249	67,690
Rest of world- total revenue
Net product revenues by geographic area
Total Revenue	13,277	9,962	26,237	15,078
Product revenue
Net product revenues by geographic area
Total Revenue	921,146	553,745	1,668,064	964,036
Product revenue | U.S. - total revenue
Net product revenues by geographic area
Total Revenue	479,365	223,539	830,821	362,307
Product revenue | China- total revenue
Net product revenues by geographic area
Total Revenue	347,112	293,922	662,774	540,828
Product revenue | Europe- total revenue
Net product revenues by geographic area
Total Revenue	81,392	26,322	148,232	45,823
Product revenue | Rest of world- total revenue
Net product revenues by geographic area
Total Revenue	13,277	9,962	26,237	15,078
Collaboration revenue
Net product revenues by geographic area
Total Revenue	8,020	41,516	12,754	79,026
Collaboration revenue | U.S. - total revenue
Net product revenues by geographic area
Total Revenue	2,065	28,808	2,065	54,523
Collaboration revenue | China- total revenue
Net product revenues by geographic area
Total Revenue	4,958	1,861	9,672	2,636
Collaboration revenue | Europe- total revenue
Net product revenues by geographic area
Total Revenue	997	10,847	1,017	21,867
Collaboration revenue | Rest of world- total revenue
Net product revenues by geographic area
Total Revenue	$ 0	$ 0	$ 0	$ 0